2. Anti-infection Cell Cycle/DNA Damage Apoptosis Metabolic Enzyme/Protease
  3. CMV DNA/RNA Synthesis Orthopoxvirus Apoptosis Endogenous Metabolite
  4. Cidofovir dihydrate

Cidofovir dihydrate  (Synonyms: GS 0504 dihydrate; HPMPC dihydrate; (S)-HPMPC dihydrate)

Cat. No.: HY-17438A
Handling Instructions Technical Support

Cidofovir (GS 0504; HPMPC; (S)-HPMPC) dihydrate is an acyclic monophosphate nucleotide analogue and CMV inhibitor with antiviral activity. Cidofovir dihydrate inhibits cytomegalovirus (CMV) replication by selectively inhibiting viral DNA polymerase. Cidofovir dihydrate induces apoptosis and can be used in studies of AIDS cytomegalovirus retinitis, herpes, and cancer. Cidofovir dihydrate also has anti-orthopoxvirus and anti-variola activities.

For research use only. We do not sell to patients.

CAS No. : 149394-66-1

Size Price Stock Quantity
5 mg Get quote 2 - 3 Weeks 1 - 2 Weeks 3 - 4 Weeks 2 - 3 weeks
10 mg Get quote 2 - 3 Weeks 1 - 2 Weeks 3 - 4 Weeks 2 - 3 weeks
50 mg Get quote 2 - 3 Weeks 1 - 2 Weeks 3 - 4 Weeks 2 - 3 weeks
100 mg Get quote 2 - 3 Weeks 1 - 2 Weeks 3 - 4 Weeks 2 - 3 weeks
200 mg   Get quote  
500 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 14 publication(s) in Google Scholar

Other Forms of Cidofovir dihydrate:

Cidofovir dihydrate Related Antibodies

Top Publications Citing Use of Products

    Cidofovir dihydrate purchased from MedChemExpress. Usage Cited in: Pharmaceuticals (Basel). 2025 Oct 16;18(10):1560.  [Abstract]

    The cytotoxicity of three reference compounds (GCV, CDV (Cidofovir), and BCV) on COS-7 cells was tested.

    Cidofovir dihydrate purchased from MedChemExpress. Usage Cited in: Virol Sin. 2025 Mar 25:S1995-820X(25)00031-8.  [Abstract]

    HEK293T cells were transfected with pHBoV1-HiBiTNS1 in the presence of Cidofovir (200 ​μM), favipiravir (50 ​μM), ivermectin (10 ​μM), nevirapine (50 ​μM), remdesivir (10 ​μM), ribavirin (50 ​μM), sofosbuvir (50 ​μM), or zidovudin (50 ​μM). At 72 ​h post-transfection, the Nano-Glo luciferase assay was performed.

    Cidofovir dihydrate purchased from MedChemExpress. Usage Cited in: J Virol. 2025 Jan 23:e0153924.  [Abstract]

    Antiviral activity of cidofovir against HBoV1. MA104 cells were treated with 50, 100, 200, 400 µM cidofovir for 6 h and then infected with HBoV1 for 12 h, and the intracellular viral DNA copies were detected at 96 h.p.i.

    Cidofovir dihydrate purchased from MedChemExpress. Usage Cited in: Poult Sci. 2024 Dec;103(12):104238.  [Abstract]

    DEFs infected DPV at MOI=1, then treated with Cidofovir (10 nmol) for 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 14 h and 16 h, qRT-PCR detected DPV copy numbers in the supernatant.

    Cidofovir dihydrate purchased from MedChemExpress. Usage Cited in: Emerg Microbes Infect. 2023 Dec;12(1):2208682.  [Abstract]

    Cytotoxicity of Cidofovir and its Inhibition efficiency on WIBP-MPXV-001

    View All DNA/RNA Synthesis Isoform Specific Products:

    View All Isoforms
    RNASE L DNA Polymerases RNA Polymerases Helicases DNA Ligase

    View All Endogenous Metabolite Isoform Specific Products:

    View All Isoforms
    Human Endogenous Metabolite Microbial Metabolite

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Cidofovir (GS 0504; HPMPC; (S)-HPMPC) dihydrate is an acyclic monophosphate nucleotide analogue and CMV inhibitor with antiviral activity. Cidofovir dihydrate inhibits cytomegalovirus (CMV) replication by selectively inhibiting viral DNA polymerase. Cidofovir dihydrate induces apoptosis and can be used in studies of AIDS cytomegalovirus retinitis, herpes, and cancer[1][3]. Cidofovir dihydrate also has anti-orthopoxvirus and anti-variola activities[4].

    IC50 & Target

    DNA Polymerase

     

    Cellular Effect
    Cell Line Type Value Description References
    A549 CC50
    50.6 μM
    Compound: 2
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by alamarBlue assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by alamarBlue assay
    		[PMID: 31711794]
    A549 EC50
    16.5 μM
    Compound: HPMPC, GS-504
    Antiviral activity against Human adenovirus type 11p slobitski infected in A549 cells assessed as inhibition of DNA replication by QPCR assay
    Antiviral activity against Human adenovirus type 11p slobitski infected in A549 cells assessed as inhibition of DNA replication by QPCR assay
    		[PMID: 20585112]
    A549 EC50
    19.9 μM
    Compound: HPMPC, GS-504
    Antiviral activity against Human adenovirus type 5 F2853-5b infected in A549 cells assessed as inhibition of DNA replication by QPCR assay
    Antiviral activity against Human adenovirus type 5 F2853-5b infected in A549 cells assessed as inhibition of DNA replication by QPCR assay
    		[PMID: 20585112]
    A549 EC50
    20 μM
    Compound: Cidofovir
    Antiviral activity against Adenovirus type 5 F2853-5b infected in human A549 cells assessed as inhibition of viral replication after 24 hrs by RT-PCR analysis
    Antiviral activity against Adenovirus type 5 F2853-5b infected in human A549 cells assessed as inhibition of viral replication after 24 hrs by RT-PCR analysis
    		[PMID: 22369233]
    BSC-1 CC50
    423.5 μM
    Compound: HPMPC
    Cytotoxicity against african green monkey BSC1 cells
    Cytotoxicity against african green monkey BSC1 cells
    		[PMID: 17420214]
    BSC-1 CC50
    > 100 μM
    Compound: cidofovir
    Cytotoxicity against african green monkey BSC1 cells assessed as ATP levels after 4 days by CellTitre-Glo Luminescent Cell Viability assay
    Cytotoxicity against african green monkey BSC1 cells assessed as ATP levels after 4 days by CellTitre-Glo Luminescent Cell Viability assay
    		[PMID: 23320521]
    BSC-1 EC50
    132 μM
    Compound: cidofovir, CDV
    Antiviral activity against Vaccinia virus WR in BSC1 cells assessed as protection from virus-induced lysis of cell monolayer after 20 hrs
    Antiviral activity against Vaccinia virus WR in BSC1 cells assessed as protection from virus-induced lysis of cell monolayer after 20 hrs
    		[PMID: 18808105]
    BSC-1 EC50
    17.8 μM
    Compound: HPMPC
    Antiviral activity against Simian virus 40 PML2 DAR in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against Simian virus 40 PML2 DAR in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17420214]
    BSC-1 EC50
    19 μM
    Compound: HPMPC
    Antiviral activity against Simian virus 40 A2895 in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against Simian virus 40 A2895 in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17420214]
    BSC-1 EC50
    19.3 μM
    Compound: HPMPC
    Antiviral activity against Simian virus 40 PML1 EK in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against Simian virus 40 PML1 EK in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17420214]
    BSC-1 EC50
    50 μM
    Compound: cidofovir, CDV
    Antiviral activity against Vaccinia virus WR in BSC1 cells assessed as reduction in plaque formation after 20 hrs
    Antiviral activity against Vaccinia virus WR in BSC1 cells assessed as reduction in plaque formation after 20 hrs
    		[PMID: 18808105]
    BSC-1 IC50
    11.5 μM
    Compound: cidofovir
    Antiviral activity against Vaccinia virus WR infected in african green monkey BSC1 cells after 4 days by plaque reduction assay
    Antiviral activity against Vaccinia virus WR infected in african green monkey BSC1 cells after 4 days by plaque reduction assay
    		[PMID: 23320521]
    Bone marrow cell CC50
    6 μM
    Compound: cidofovir
    Cytotoxicity against human bone marrow cells assessed as inhibition of CFU-GM formation after 15 days
    Cytotoxicity against human bone marrow cells assessed as inhibition of CFU-GM formation after 15 days
    		[PMID: 17329103]
    C-33-A CC50
    > 300 μM
    Compound: Cidofovir
    Cytotoxicity in human C-33-A cells by CellTiter-Glo reagent assay
    Cytotoxicity in human C-33-A cells by CellTiter-Glo reagent assay
    		[PMID: 27933957]
    C3H EC50
    > 4 μg/mL
    Compound: HPMPC, cidofovir
    Antiviral activity against MSV in C3H cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against MSV in C3H cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17948980]
    CCRF-CEM CC50
    > 200 μM
    Compound: Cidofovir
    Compound concentration required to reduce viability of CEM cells
    Compound concentration required to reduce viability of CEM cells
    		[PMID: 14643328]
    CCRF-CEM EC50
    > 10 μM
    Compound: Cidofovir
    Antiviral activity against HIV1 IIIB in CEM cells
    Antiviral activity against HIV1 IIIB in CEM cells
    		[PMID: 16392791]
    CCRF-CEM EC50
    > 10 μM
    Compound: Cidofovir
    Antiviral activity against HIV2 ROD in CEM cells
    Antiviral activity against HIV2 ROD in CEM cells
    		[PMID: 16392791]
    CCRF-CEM EC50
    > 200 μM
    Compound: Cidofovir
    Compound was tested for anti-viral activity against HIV-1 in CEM cells
    Compound was tested for anti-viral activity against HIV-1 in CEM cells
    		[PMID: 14643328]
    CCRF-CEM EC50
    > 200 μM
    Compound: Cidofovir
    Compound was tested for anti-viral activity against HIV-2 in CEM cells
    Compound was tested for anti-viral activity against HIV-2 in CEM cells
    		[PMID: 14643328]
    CCRF-CEM EC50
    > 20 μg/mL
    Compound: HPMPC, cidofovir
    Antiviral activity against HIV1 3B in CEM cells assessed as reduction of virus-induced cytopathogenicity after 4 days
    Antiviral activity against HIV1 3B in CEM cells assessed as reduction of virus-induced cytopathogenicity after 4 days
    		[PMID: 17948980]
    CCRF-CEM EC50
    > 20 μg/mL
    Compound: HPMPC, cidofovir
    Antiviral activity against HIV2 ROD in CEM cells assessed as reduction of virus-induced cytopathogenicity after 4 days
    Antiviral activity against HIV2 ROD in CEM cells assessed as reduction of virus-induced cytopathogenicity after 4 days
    		[PMID: 17948980]
    CHO CC50
    255 μM
    Compound: Cidofovir
    Cytotoxicity against CHO cells expressing hOAT1 after 120 hrs by Cell-Titer Glo assay
    Cytotoxicity against CHO cells expressing hOAT1 after 120 hrs by Cell-Titer Glo assay
    		[PMID: 19001108]
    CHO CC50
    520 μM
    Compound: Cidofovir
    Cytotoxicity against CHO cells after 120 hrs by Cell-Titer Glo assay
    Cytotoxicity against CHO cells after 120 hrs by Cell-Titer Glo assay
    		[PMID: 19001108]
    CHO CC50
    >= 2000 μM
    Compound: Cidofovir
    Ratio of CC50 for CHO cells to CC50 for CHO cells expressing hOAT1 after 120 hrs by Cell-Titer Glo assay
    Ratio of CC50 for CHO cells to CC50 for CHO cells expressing hOAT1 after 120 hrs by Cell-Titer Glo assay
    		[PMID: 19001108]
    CHO IC50
    60 μM
    Compound: Cidofovir
    TP_TRANSPORTER: inhibition of 6-Carboxyfluorescein uptake in OAT1-expressing CHO cells
    TP_TRANSPORTER: inhibition of 6-Carboxyfluorescein uptake in OAT1-expressing CHO cells
    		[PMID: 10929807]
    COS-7 CC50
    49 μM
    Compound: Cidofovir
    Cytotoxicity against JC polyomavirus MAD-4 infected grivet COS7 cells assessed as reduction in cell viability after 7 days by cell titer-glo assay
    Cytotoxicity against JC polyomavirus MAD-4 infected grivet COS7 cells assessed as reduction in cell viability after 7 days by cell titer-glo assay
    		[PMID: 27624078]
    COS-7 EC50
    2 μM
    Compound: Cidofovir
    Antiviral activity against JC polyomavirus MAD-4 infected in grivet COS7 cells assessed as reduction in DNA copy number after 7 days by PCR analysis
    Antiviral activity against JC polyomavirus MAD-4 infected in grivet COS7 cells assessed as reduction in DNA copy number after 7 days by PCR analysis
    		[PMID: 27624078]
    Ca-Ski EC50
    > 100000 nM
    Compound: Cidofovir
    Antiproliferative activity against HPV-transformed human CaSki cells after 7 days by SRB assay
    Antiproliferative activity against HPV-transformed human CaSki cells after 7 days by SRB assay
    		[PMID: 19398642]
    HEK293 CC50
    > 300 μM
    Compound: Cidofovir
    Cytotoxicity in HEK293 cells by XTT assay
    Cytotoxicity in HEK293 cells by XTT assay
    		[PMID: 27933957]
    HEL CC50
    121 μM
    Compound: cidofovir
    Cytotoxicity against HEL cells
    Cytotoxicity against HEL cells
    		[PMID: 17518459]
    HEL CC50
    133 μM
    Compound: cidofovir
    Cytotoxicity against human HEL cells assessed as reduction of cell growth
    Cytotoxicity against human HEL cells assessed as reduction of cell growth
    		[PMID: 17672445]
    HEL CC50
    150.02 μM
    Compound: Cidofovir
    Cytotoxicity against human HEL cells assessed as reduce in cell growth incubated for 3 days by coulter counter analysis
    Cytotoxicity against human HEL cells assessed as reduce in cell growth incubated for 3 days by coulter counter analysis
    		[PMID: 33479570]
    HEL CC50
    153 μM
    Compound: Cidofovir
    Cytotoxicity against human HEL cells assessed as cell growth reduction incubated for 3 days
    Cytotoxicity against human HEL cells assessed as cell growth reduction incubated for 3 days
    		[PMID: 26291038]
    HEL CC50
    158 μM
    Compound: Cidofovir
    Cytostatic concentration required to inhibit HEL cell proliferation measured at day 4
    Cytostatic concentration required to inhibit HEL cell proliferation measured at day 4
    		[PMID: 15027877]
    HEL CC50
    161 μM
    Compound: Cidofovir
    Cytotoxicity against HEL
    Cytotoxicity against HEL
    		[PMID: 23743443]
    HEL CC50
    175 μM
    Compound: Cidofovir
    Cytotoxicity against HEL cells assessed as reduction of cell growth
    Cytotoxicity against HEL cells assessed as reduction of cell growth
    		[PMID: 20064723]
    HEL CC50
    21.3 μg/mL
    Compound: HPMC (Cidofovir)
    Cytotoxic concentration to reduce the 50% cell growth of human embryonic lung cells
    Cytotoxic concentration to reduce the 50% cell growth of human embryonic lung cells
    		[PMID: 15658861]
    HEL CC50
    21.3 μg/mL
    Compound: HPMC (Cidofovir)
    Cytotoxic concentration to reduce the 50% cell growth of human embryonic lung cells
    Cytotoxic concentration to reduce the 50% cell growth of human embryonic lung cells
    		[PMID: 15658861]
    HEL CC50
    216 μM
    Compound: Cidofovir
    Cytotoxicity against HEL cells assessed as reduction in cell growth after 3 days by coulter counter method
    Cytotoxicity against HEL cells assessed as reduction in cell growth after 3 days by coulter counter method
    		[PMID: 28757102]
    HEL CC50
    234 μM
    Compound: 2, (S)-HPMPC
    Cytotoxicity against human HEL cells assessed as growth inhibition after 3 days by coulter counter
    Cytotoxicity against human HEL cells assessed as growth inhibition after 3 days by coulter counter
    		[PMID: 21565516]
    HEL CC50
    23 μg/mL
    Compound: cidofovir
    Cytotoxicity against HEL cells
    Cytotoxicity against HEL cells
    		[PMID: 16480257]
    HEL CC50
    241 μM
    Compound: Cidofovir
    Cytotoxicity against HEL cells assessed as effect on cell growth incubated for 3 days by Coulter counter assay
    Cytotoxicity against HEL cells assessed as effect on cell growth incubated for 3 days by Coulter counter assay
    		[PMID: 22858222]
    HEL CC50
    254 μM
    Compound: Cidofovir
    Cytotoxicity against human HEL cells after 3 days by coulter counter
    Cytotoxicity against human HEL cells after 3 days by coulter counter
    		[PMID: 21745746]
    HEL CC50
    280 μM
    Compound: (S)-CDV, HPMPC
    Cytotoxicity against human HEL cells after 3 days
    Cytotoxicity against human HEL cells after 3 days
    		[PMID: 21128666]
    HEL CC50
    317 μM
    Compound: cidofovir
    Inhibition of cell growth in HEL cells.
    Inhibition of cell growth in HEL cells.
    		[PMID: 10966745]
    HEL CC50
    35.4 μg/mL
    Compound: Cidofovir
    Cytotoxicity against HEL
    Cytotoxicity against HEL
    		10.1007/s00044-011-9776-0
    HEL CC50
    400 μg/mL
    Compound: Cidofovir
    Cytotoxicity against Cytomegalovirus infected HEL cells assessed as change in cell morphology
    Cytotoxicity against Cytomegalovirus infected HEL cells assessed as change in cell morphology
    		[PMID: 19324473]
    HEL CC50
    47 μg/mL
    Compound: cidofovir
    Cytotoxicity against HEL cells assessed as reduction of cell growth after 3 days
    Cytotoxicity against HEL cells assessed as reduction of cell growth after 3 days
    		[PMID: 17869124]
    HEL CC50
    47 μg/mL
    Compound: cidofovir
    Cytotoxicity against HEL cells assessed as reduction of growth after 3 days
    Cytotoxicity against HEL cells assessed as reduction of growth after 3 days
    		[PMID: 18835175]
    HEL CC50
    51 μM
    Compound: cidofovir
    Cytotoxicity against HEL cells assessed as cell growth after 7 days
    Cytotoxicity against HEL cells assessed as cell growth after 7 days
    		[PMID: 17539622]
    HEL CC50
    51 μM
    Compound: cidofovir
    Cytotoxicity against HEL cells assessed as reduction in cell growth
    Cytotoxicity against HEL cells assessed as reduction in cell growth
    		[PMID: 17961851]
    HEL CC50
    511 μM
    Compound: (S)-HPMPC
    Cytotoxicity against HEL
    Cytotoxicity against HEL
    		[PMID: 20809641]
    HEL CC50
    54 μM
    Compound: Cidofovir
    Cytotoxicity against human HEL cells assessed as reduction in cell growth after 3 days
    Cytotoxicity against human HEL cells assessed as reduction in cell growth after 3 days
    		[PMID: 19339082]
    HEL CC50
    57 μg/mL
    Compound: Cidofovir
    Cytotoxicity against Cytomegalovirus infected HEL cells assessed as reduction in cell growth
    Cytotoxicity against Cytomegalovirus infected HEL cells assessed as reduction in cell growth
    		[PMID: 19324473]
    HEL CC50
    64 μM
    Compound: Cidofovir
    Cytostatic against human HEL cells assessed as reduction in cell growth after 3 days by coulter counter
    Cytostatic against human HEL cells assessed as reduction in cell growth after 3 days by coulter counter
    		[PMID: 22578783]
    HEL CC50
    74 μM
    Compound: HPMPC, Cidofovir
    Cytotoxicity against human HEL cells assessed as reduction of growth after 3 days
    Cytotoxicity against human HEL cells assessed as reduction of growth after 3 days
    		[PMID: 19226140]
    HEL CC50
    76 μg/mL
    Compound: HPMPC, cidofovir
    Cytotoxicity against HEL cells assessed as cell growth after 3 days
    Cytotoxicity against HEL cells assessed as cell growth after 3 days
    		[PMID: 17948980]
    HEL CC50
    > 150 μM
    Compound: (S)-HPMPC (cidofovir)
    Cytotoxic concentration required to reduce HEL cell growth by 50%
    Cytotoxic concentration required to reduce HEL cell growth by 50%
    		[PMID: 15081019]
    HEL CC50
    > 150 μM
    Compound: Cidofovir
    Cytotoxic concentration required to reduce HEL cell growth
    Cytotoxic concentration required to reduce HEL cell growth
    		[PMID: 15801851]
    HEL CC50
    > 200 μg/mL
    Compound: (S)-HPMPC
    Cytotoxic concentration required to reduce cell growth HEL cells (after 3 days) by 50 %
    Cytotoxic concentration required to reduce cell growth HEL cells (after 3 days) by 50 %
    		10.1016/0960-894X(95)00278-2
    HEL CC50
    > 250 μM
    Compound: Cidofovir
    Cytotoxicity against HEL cells after 3 days by coulter counter analysis
    Cytotoxicity against HEL cells after 3 days by coulter counter analysis
    		[PMID: 21232828]
    HEL CC50
    > 300 μM
    Compound: Cidofovir
    Cytotoxicity against HEL cells infected with Cytomegalovirus assessed as growth inhibition
    Cytotoxicity against HEL cells infected with Cytomegalovirus assessed as growth inhibition
    		[PMID: 27750154]
    HEL CC50
    > 300 μM
    Compound: Cidofovir
    Cytostatic activity against HEL cells after 3 days by Coulter counting method
    Cytostatic activity against HEL cells after 3 days by Coulter counting method
    		[PMID: 29407990]
    HEL CC50
    > 300 μM
    Compound: Cidofovir
    Cytotoxicity against human HEL cells assessed as reduction in cell viability measured after 3 days by beckman coulter counting method
    Cytotoxicity against human HEL cells assessed as reduction in cell viability measured after 3 days by beckman coulter counting method
    		[PMID: 33894564]
    HEL CC50
    > 317 μM
    Compound: HPMPC
    Cytotoxicity against human HEL cells assessed as reduction in cell proliferation incubated for 3 days by Coulter counter method
    Cytotoxicity against human HEL cells assessed as reduction in cell proliferation incubated for 3 days by Coulter counter method
    		[PMID: 32676147]
    HEL CC50
    > 350 μM
    Compound: Cidofovir
    Compound concentration required to reduce viability of HEL cells
    Compound concentration required to reduce viability of HEL cells
    		[PMID: 14643328]
    HEL CC50
    > 350 μM
    Compound: Cidofovir
    Cytotoxicity against human HEL cells after 3 days by Coulter counting method
    Cytotoxicity against human HEL cells after 3 days by Coulter counting method
    		[PMID: 23911854]
    HEL CC50
    > 358 μM
    Compound: Cidofovir
    Cytotoxic activity against HEL cells assessed as reduction in cell proliferation after 3 days by coulter counting method
    Cytotoxic activity against HEL cells assessed as reduction in cell proliferation after 3 days by coulter counting method
    		[PMID: 28682067]
    HEL CC50
    > 358 μM
    Compound: Cidofovir
    Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method
    Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method
    		[PMID: 29268134]
    HEL CC50
    > 358 μM
    Compound: Cidofovir
    Cytostatic activity against HEL cells after 3 days by Coulter counting method
    Cytostatic activity against HEL cells after 3 days by Coulter counting method
    		[PMID: 29550734]
    HEL CC50
    > 358 μM
    Compound: Cidofovir
    Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method
    Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method
    		[PMID: 29670705]
    HEL CC50
    > 50 μg/mL
    Compound: Cidofovir
    Cytotoxic concentration reducing HEL cell growth by 50%.
    Cytotoxic concentration reducing HEL cell growth by 50%.
    		[PMID: 12217359]
    HEL CC50
    >= 18 μg/mL
    Compound: Cidofovir
    Cytotoxicity against human HEL cells assessed as reduction of cell growth
    Cytotoxicity against human HEL cells assessed as reduction of cell growth
    		[PMID: 17583388]
    HEL CC50
    >= 208 μM
    Compound: CDV
    Cytotoxicity against human cytomegalovirus infected HEL cells assessed as cell growth inhibition incubated for 3 days by coulter counter method
    Cytotoxicity against human cytomegalovirus infected HEL cells assessed as cell growth inhibition incubated for 3 days by coulter counter method
    		[PMID: 26443550]
    HEL EC50
    0.0095 μg/mL
    Compound: Cidofovir
    Antiviral activity against Varicella Zoster Virus OKA infected in HEL cells assessed as reduction in virus plaque formation
    Antiviral activity against Varicella Zoster Virus OKA infected in HEL cells assessed as reduction in virus plaque formation
    		[PMID: 19324473]
    HEL EC50
    0.03 μg/mL
    Compound: HPMPC, cidofovir
    Antiviral activity against VZV 07-1 TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against VZV 07-1 TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17948980]
    HEL EC50
    0.044 μM
    Compound: (S)-CDV, HPMPC
    Antiviral activity against VZV OKA expressing thymidine kinase infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 5 days
    Antiviral activity against VZV OKA expressing thymidine kinase infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 5 days
    		[PMID: 21128666]
    HEL EC50
    0.045 μM
    Compound: HPMPC, Cidofovir
    Antiviral activity against foscarnet-resistant HCMV AD169 clone C infected in HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against foscarnet-resistant HCMV AD169 clone C infected in HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 19226140]
    HEL EC50
    0.069 μM
    Compound: HPMPC, Cidofovir
    Antiviral activity against wild type HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against wild type HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 19226140]
    HEL EC50
    0.069 μg/mL
    Compound: (S)-HPMPC, cidofovir
    Antiviral activity against acyclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against acyclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 18707089]
    HEL EC50
    0.07 μM
    Compound: (S)-CDV, HPMPC
    Antiviral activity against thymidine kinase-deficient VZV 07/1 infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 5 days
    Antiviral activity against thymidine kinase-deficient VZV 07/1 infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 5 days
    		[PMID: 21128666]
    HEL EC50
    0.073 μg/mL
    Compound: (S)-HPMPC, cidofovir
    Antiviral activity against TK- VZV 07-1 in HEL cells assessed as inhibition of plaque formation
    Antiviral activity against TK- VZV 07-1 in HEL cells assessed as inhibition of plaque formation
    		[PMID: 17298047]
    HEL EC50
    0.075 μg/mL
    Compound: Cidofovir
    Antiviral activity against human cytomegalovirus AD169 infected HEL cells assessed as reduction in virus plaque formation
    Antiviral activity against human cytomegalovirus AD169 infected HEL cells assessed as reduction in virus plaque formation
    		[PMID: 17583388]
    HEL EC50
    0.076 μM
    Compound: HPMPC, Cidofovir
    Antiviral activity against wild type HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against wild type HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 19226140]
    HEL EC50
    0.077 μg/mL
    Compound: (S)-HPMPC, cidofovir
    Antiviral activity against VZV OKA in HEL cells assessed as inhibition of plaque formation
    Antiviral activity against VZV OKA in HEL cells assessed as inhibition of plaque formation
    		[PMID: 17298047]
    HEL EC50
    0.092 μM
    Compound: HPMPC, Cidofovir
    Antiviral activity against PMEDAP-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against PMEDAP-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 19226140]
    HEL EC50
    0.095 μM
    Compound: HPMPC, Cidofovir
    Antiviral activity against acyclovir-resistant HCMV AD169 clone 1 infected in HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against acyclovir-resistant HCMV AD169 clone 1 infected in HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 19226140]
    HEL EC50
    0.09 μg/mL
    Compound: (S)-HPMPC, cidofovir
    Antiviral activity against HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 17298047]
    HEL EC50
    0.09 μg/mL
    Compound: HPMPC, cidofovir
    Antiviral activity against VZV OKA in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against VZV OKA in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17948980]
    HEL EC50
    0.1 μM
    Compound: 2, (S)-HPMPC
    Antiviral activity against VZV 07/1 infected in HEL cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against VZV 07/1 infected in HEL cells assessed as protection against virus-induced cytopathicity
    		[PMID: 21565516]
    HEL EC50
    0.102 μM
    Compound: Cidofovir
    Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus plaque formation after 4 days
    Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus plaque formation after 4 days
    		[PMID: 22459876]
    HEL EC50
    0.12 μg/mL
    Compound: cidofovir
    Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 5 days
    Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 5 days
    		[PMID: 17869124]
    HEL EC50
    0.12 μg/mL
    Compound: cidofovir
    Antiviral activity against human cytomegalovirus Davis in HEL cells assessed as inhibition of viral cytopathicity
    Antiviral activity against human cytomegalovirus Davis in HEL cells assessed as inhibition of viral cytopathicity
    		[PMID: 18835175]
    HEL EC50
    0.15 μg/mL
    Compound: HPMPC, cidofovir
    Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17948980]
    HEL EC50
    0.16 μM
    Compound: (S)-HPMPC (cidofovir)
    Effective concentration against human cytomegalovirus AD-169 strain in HEL cell cultures
    Effective concentration against human cytomegalovirus AD-169 strain in HEL cell cultures
    		[PMID: 15081019]
    HEL EC50
    0.18 μg/mL
    Compound: Cidofovir
    Effective concentration against AD-169 strain of CMV virus expressed in HEL cells
    Effective concentration against AD-169 strain of CMV virus expressed in HEL cells
    		[PMID: 15689173]
    HEL EC50
    0.18 μg/mL
    Compound: HPMPC, cidofovir
    Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17948980]
    HEL EC50
    0.1 μg/mL
    Compound: (S)-HPMPC, cidofovir
    Antiviral activity against foscarnet-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against foscarnet-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 18707089]
    HEL EC50
    0.1 μg/mL
    Compound: cidofovir
    Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 5 days
    Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 5 days
    		[PMID: 17869124]
    HEL EC50
    0.1 μg/mL
    Compound: cidofovir
    Antiviral activity against human cytomegalovirus AD169 in HEL cells assessed as inhibition of viral cytopathicity
    Antiviral activity against human cytomegalovirus AD169 in HEL cells assessed as inhibition of viral cytopathicity
    		[PMID: 18835175]
    HEL EC50
    0.24 μg/mL
    Compound: Cidofovir
    Antiviral activity against Cytomegalovirus AD169 infected in HEL cells assessed as reduction in virus plaque formation
    Antiviral activity against Cytomegalovirus AD169 infected in HEL cells assessed as reduction in virus plaque formation
    		[PMID: 19324473]
    HEL EC50
    0.29 μM
    Compound: 2, (S)-HPMPC
    Antiviral activity against VZV OKA infected in HEL cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against VZV OKA infected in HEL cells assessed as protection against virus-induced cytopathicity
    		[PMID: 21565516]
    HEL EC50
    0.29 μg/mL
    Compound: Cidofovir
    Effective concentration against Davis strain of CMV virus expressed in HEL cells
    Effective concentration against Davis strain of CMV virus expressed in HEL cells
    		[PMID: 15689173]
    HEL EC50
    0.2 μg/mL
    Compound: (S)-HPMPC, cidofovir
    Antiviral activity against HCMV AD169 in HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against HCMV AD169 in HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 17298047]
    HEL EC50
    0.2 μg/mL
    Compound: Cidofovir
    Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    		[PMID: 20971531]
    HEL EC50
    0.2 μg/mL
    Compound: HPMPC, cidofovir
    Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17948980]
    HEL EC50
    0.3 μM
    Compound: Cidofovir
    Antiviral activity against HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 21232828]
    HEL EC50
    0.3 μM
    Compound: HPMPC, Cidofovir
    Antiviral activity against HCMV AD169 infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection
    Antiviral activity against HCMV AD169 infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection
    		[PMID: 19226140]
    HEL EC50
    0.35 μg/mL
    Compound: (S)-HPMPC, cidofovir
    Antiviral activity against HSV2 G in HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against HSV2 G in HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 17298047]
    HEL EC50
    0.369 μM
    Compound: Cidofovir
    Antiviral activity against Cytomegalovirus AD-169 infected in HEL cells assessed as inhibition of virus plaque formation after 4 days
    Antiviral activity against Cytomegalovirus AD-169 infected in HEL cells assessed as inhibition of virus plaque formation after 4 days
    		[PMID: 22459876]
    HEL EC50
    0.37 μg/mL
    Compound: Cidofovir
    Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction in virus plaque formation
    Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction in virus plaque formation
    		[PMID: 19324473]
    HEL EC50
    0.38 μM
    Compound: Cidofovir
    Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus plaque formation
    Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus plaque formation
    		[PMID: 27639368]
    HEL EC50
    0.38 μg/mL
    Compound: (S)-HPMPC, cidofovir
    Antiviral activity against ACV-resistant TK- HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against ACV-resistant TK- HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 17298047]
    HEL EC50
    0.3 μg/mL
    Compound: (S)-HPMPC, cidofovir
    Antiviral activity against HCMV Davis in HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against HCMV Davis in HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 17298047]
    HEL EC50
    0.3 μg/mL
    Compound: Cidofovir
    Antiviral activity against Human herpesvirus 5 Davis infected human HEL cells assessed as reduction in the virus plaque formation
    Antiviral activity against Human herpesvirus 5 Davis infected human HEL cells assessed as reduction in the virus plaque formation
    		10.1007/s00044-011-9776-0
    HEL EC50
    0.4 μM
    Compound: Cidofovir
    Antiviral activity against HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 21232828]
    HEL EC50
    0.4 μM
    Compound: Cidofovir
    Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation
    Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation
    		[PMID: 27639368]
    HEL EC50
    0.41 μM
    Compound: Cidofovir
    Antiviral activity against human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection
    Antiviral activity against human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection
    		[PMID: 19339082]
    HEL EC50
    0.41 μM
    Compound: cidofovir
    Antiviral activity against human cytomegalovirus AD169 in HEL cells assessed as reduction of plaque formation after 7 days
    Antiviral activity against human cytomegalovirus AD169 in HEL cells assessed as reduction of plaque formation after 7 days
    		[PMID: 17539622]
    HEL EC50
    0.41 μM
    Compound: cidofovir
    Antiviral activity against human cytomegalovirus Davis in HEL cells assessed as reduction of plaque formation after 7days
    Antiviral activity against human cytomegalovirus Davis in HEL cells assessed as reduction of plaque formation after 7days
    		[PMID: 17539622]
    HEL EC50
    0.41 μM
    Compound: cidofovir
    Antiviral activity against HCMV AD169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days
    Antiviral activity against HCMV AD169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days
    		[PMID: 17961851]
    HEL EC50
    0.41 μM
    Compound: cidofovir
    Antiviral activity against HCMV Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days
    Antiviral activity against HCMV Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days
    		[PMID: 17961851]
    HEL EC50
    0.42 μg/mL
    Compound: HPMPC, cidofovir
    Antiviral activity against HSV2 Lyons in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against HSV2 Lyons in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17948980]
    HEL EC50
    0.42 μg/mL
    Compound: HPMPC, cidofovir
    Antiviral activity against acyclovir-resistant HSV1 KOS TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against acyclovir-resistant HSV1 KOS TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17948980]
    HEL EC50
    0.43 μg/mL
    Compound: (S)-HPMPC, cidofovir
    Antiviral activity against HSV2 Lyons in HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against HSV2 Lyons in HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 17298047]
    HEL EC50
    0.49 μg/mL
    Compound: (S)-HPMPC, cidofovir
    Antiviral activity against HCMV 6 with U97 mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against HCMV 6 with U97 mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 18707089]
    HEL EC50
    0.4 μg/mL
    Compound: Cidofovir
    Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    		[PMID: 20971531]
    HEL EC50
    0.5 μM
    Compound: (S)-HPMPC (cidofovir)
    Effective concentration against human cytomegalovirus Davies strain in HEL cell cultures
    Effective concentration against human cytomegalovirus Davies strain in HEL cell cultures
    		[PMID: 15081019]
    HEL EC50
    0.5 μM
    Compound: HPMPC, Cidofovir
    Antiviral activity against HCMV Davis infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection
    Antiviral activity against HCMV Davis infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection
    		[PMID: 19226140]
    HEL EC50
    0.51 μM
    Compound: Cidofovir
    Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus plaque formation
    Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus plaque formation
    		[PMID: 23911856]
    HEL EC50
    0.51 μM
    Compound: Cidofovir
    Antiviral activity against Human cytomegalovirus Davis expressed in HEL cells assessed as reduction in plaque formation incubated for 7 days by Giemsa stain based microscopy
    Antiviral activity against Human cytomegalovirus Davis expressed in HEL cells assessed as reduction in plaque formation incubated for 7 days by Giemsa stain based microscopy
    		[PMID: 26291038]
    HEL EC50
    0.51 μM
    Compound: Cidofovir
    Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus plaque formation
    Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus plaque formation
    		[PMID: 27639368]
    HEL EC50
    0.55 μM
    Compound: HPMPC, Cidofovir
    Antiviral activity against HPMPA-resistant HCMV AD169 clone 2 mutant infected in HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against HPMPA-resistant HCMV AD169 clone 2 mutant infected in HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 19226140]
    HEL EC50
    0.57 μM
    Compound: Cidofovir
    Compound was tested for anti-viral activity against HSV-1(KOS) in HEL cells
    Compound was tested for anti-viral activity against HSV-1(KOS) in HEL cells
    		[PMID: 14643328]
    HEL EC50
    0.57 μM
    Compound: Cidofovir
    Antiviral activity against HSV1 KOS in HEL cells
    Antiviral activity against HSV1 KOS in HEL cells
    		[PMID: 16392791]
    HEL EC50
    0.59 μg/mL
    Compound: (S)-HPMPC, cidofovir
    Antiviral activity against ganciclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against ganciclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 18707089]
    HEL EC50
    0.6 μM
    Compound: Cidofovir
    Effective concentration required to inhibit HCMV AD169 strain-induced cytopathicity in human embryonic lung (HEL) fibroblast cell cultures at day 7 of postinfection
    Effective concentration required to inhibit HCMV AD169 strain-induced cytopathicity in human embryonic lung (HEL) fibroblast cell cultures at day 7 of postinfection
    		[PMID: 15027877]
    HEL EC50
    0.6 μM
    Compound: Cidofovir
    Effective concentration required to inhibit human cytomegalo virus AD-169 induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection
    Effective concentration required to inhibit human cytomegalo virus AD-169 induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection
    		[PMID: 15801851]
    HEL EC50
    0.61 μM
    Compound: Cidofovir
    Antiviral activity against Human cytomegalovirus AD169 expressed in HEL cells assessed as reduction in plaque formation incubated for 7 days by Giemsa stain based microscopy
    Antiviral activity against Human cytomegalovirus AD169 expressed in HEL cells assessed as reduction in plaque formation incubated for 7 days by Giemsa stain based microscopy
    		[PMID: 26291038]
    HEL EC50
    0.62 μg/mL
    Compound: (S)-HPMPC, cidofovir
    Antiviral activity against HCMV 530 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against HCMV 530 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 18707089]
    HEL EC50
    0.64 μg/mL
    Compound: Cidofovir
    Antiviral activity against human cytomegalovirus Davis infected HEL cells assessed as reduction in virus plaque formation
    Antiviral activity against human cytomegalovirus Davis infected HEL cells assessed as reduction in virus plaque formation
    		[PMID: 17583388]
    HEL EC50
    0.65 μg/mL
    Compound: HPMPC, cidofovir
    Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17948980]
    HEL EC50
    0.66 μM
    Compound: cidofovir
    Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation
    Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation
    		[PMID: 17518459]
    HEL EC50
    0.66 μM
    Compound: cidofovir
    Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation
    Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation
    		[PMID: 17518459]
    HEL EC50
    0.67 μM
    Compound: cidofovir
    Antiviral activity against CMV AD169 in human HEL cells after 7 days
    Antiviral activity against CMV AD169 in human HEL cells after 7 days
    		[PMID: 17672445]
    HEL EC50
    0.67 μM
    Compound: cidofovir
    Antiviral activity against CMV Davis in human HEL cells after 7 days
    Antiviral activity against CMV Davis in human HEL cells after 7 days
    		[PMID: 17672445]
    HEL EC50
    0.7 μM
    Compound: Cidofovir
    Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus plaque formation
    Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus plaque formation
    		[PMID: 27639368]
    HEL EC50
    0.74 μM
    Compound: HPMPC, Cidofovir
    Antiviral activity against ganciclovir-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against ganciclovir-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 19226140]
    HEL EC50
    0.79 μg/mL
    Compound: (S)-HPMPC, cidofovir
    Antiviral activity against HCMV 521 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against HCMV 521 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 18707089]
    HEL EC50
    0.8 μM
    Compound: Cidofovir
    Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 21232828]
    HEL EC50
    0.8 μM
    Compound: Cidofovir
    Antiviral activity against thymidine kinase deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against thymidine kinase deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 21232828]
    HEL EC50
    0.83 μM
    Compound: CDV
    Antiviral activity against human cytomegalovirus AD169 infected in HEL cells assessed as reduction in viral plaque formation
    Antiviral activity against human cytomegalovirus AD169 infected in HEL cells assessed as reduction in viral plaque formation
    		[PMID: 26443550]
    HEL EC50
    0.84 μM
    Compound: CDV
    Antiviral activity against human cytomegalovirus Davis infected in HEL cells assessed as reduction in viral plaque formation
    Antiviral activity against human cytomegalovirus Davis infected in HEL cells assessed as reduction in viral plaque formation
    		[PMID: 26443550]
    HEL EC50
    0.86 μM
    Compound: Cidofovir
    Antiviral activity against Cytomegalovirus AD-169 infected in human HEL cells assessed as reduction of plaque formation
    Antiviral activity against Cytomegalovirus AD-169 infected in human HEL cells assessed as reduction of plaque formation
    		[PMID: 23811093]
    HEL EC50
    0.8 μg/mL
    Compound: Cidofovir
    Antiviral activity against Human herpesvirus 5 strain AD169 infected human HEL cells assessed as reduction in the virus plaque formation
    Antiviral activity against Human herpesvirus 5 strain AD169 infected human HEL cells assessed as reduction in the virus plaque formation
    		10.1007/s00044-011-9776-0
    HEL EC50
    0.9 μM
    Compound: Cidofovir
    Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction of viral plaque formation
    Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction of viral plaque formation
    		[PMID: 20064723]
    HEL EC50
    0.9 μM
    Compound: Cidofovir
    Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
    Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
    		[PMID: 22459876]
    HEL EC50
    0.9 μM
    Compound: Cidofovir
    Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
    Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
    		[PMID: 22459876]
    HEL EC50
    0.9 μM
    Compound: Cidofovir
    Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 23099097]
    HEL EC50
    0.9 μM
    Compound: Cidofovir
    Antiviral activity against Human simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis
    Antiviral activity against Human simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis
    		[PMID: 23603046]
    HEL EC50
    0.9 μM
    Compound: Cidofovir
    Antiviral activity against Human simplex virus 2 G infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis
    Antiviral activity against Human simplex virus 2 G infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis
    		[PMID: 23603046]
    HEL EC50
    0.9 μM
    Compound: Cidofovir
    Antiviral activity against thymidine kinase-deficient Human simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis
    Antiviral activity against thymidine kinase-deficient Human simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis
    		[PMID: 23603046]
    HEL EC50
    0.92 μM
    Compound: 2, (S)-HPMPC
    Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as protection against virus-induced cytopathicity
    		[PMID: 21565516]
    HEL EC50
    0.92 μM
    Compound: Cidofovir
    Antiviral activity against HCMV Davis infected in HEL cells by viral CPE assay
    Antiviral activity against HCMV Davis infected in HEL cells by viral CPE assay
    		[PMID: 22858222]
    HEL EC50
    0.92 μM
    Compound: Cidofovir
    Antiviral activity against Cytomegalovirus AD-169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against Cytomegalovirus AD-169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 26001344]
    HEL EC50
    0.93 μM
    Compound: Cidofovir
    Antiviral activity against HSV1 KOS infected in HEL cells by viral CPE assay
    Antiviral activity against HSV1 KOS infected in HEL cells by viral CPE assay
    		[PMID: 22858222]
    HEL EC50
    0.94 μM
    Compound: 2, (S)-HPMPC
    Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as protection against virus-induced cytopathicity
    		[PMID: 21565516]
    HEL EC50
    0.94 μM
    Compound: HPMPC
    Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity measured after 6 to 7 days
    Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity measured after 6 to 7 days
    		[PMID: 32676147]
    HEL EC50
    1 μM
    Compound: CDF
    Antiviral activity against HSV2 G in human HEL cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against HSV2 G in human HEL cells assessed as protection against virus-induced cytopathicity
    		[PMID: 19281225]
    HEL EC50
    1 μM
    Compound: CDF
    Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity
    		[PMID: 19281225]
    HEL EC50
    1 μM
    Compound: Cidofovir
    Effective concentration required to inhibit HCMV Davis strain-induced cytopathicity in human embryonic lung (HEL) fibroblast cell cultures at day 7 of postinfection
    Effective concentration required to inhibit HCMV Davis strain-induced cytopathicity in human embryonic lung (HEL) fibroblast cell cultures at day 7 of postinfection
    		[PMID: 15027877]
    HEL EC50
    1 μM
    Compound: Cidofovir
    Effective concentration required to inhibit human cytomegalo virus Davis induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection
    Effective concentration required to inhibit human cytomegalo virus Davis induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection
    		[PMID: 15801851]
    HEL EC50
    1 μM
    Compound: Cidofovir
    Antiviral activity against Cytomegalovirus AD169 infected in HEL cells assessed as reduction of viral plaque formation
    Antiviral activity against Cytomegalovirus AD169 infected in HEL cells assessed as reduction of viral plaque formation
    		[PMID: 20064723]
    HEL EC50
    1 μM
    Compound: Cidofovir
    Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as reduction in virus-induced cytopathicity
    Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as reduction in virus-induced cytopathicity
    		[PMID: 22578783]
    HEL EC50
    1 μM
    Compound: Cidofovir
    Antiviral activity against human Cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity after
    Antiviral activity against human Cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity after
    		[PMID: 23911854]
    HEL EC50
    1 μM
    Compound: Cidofovir
    Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity
    Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity
    		[PMID: 23911856]
    HEL EC50
    1 μM
    Compound: Cidofovir
    Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 26001344]
    HEL EC50
    1 μM
    Compound: Cidofovir
    Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 26001344]
    HEL EC50
    1 μM
    Compound: HPMPC, Cidofovir
    Antiviral activity against cidofovir HCMV AD169 clone 5 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against cidofovir HCMV AD169 clone 5 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 19226140]
    HEL EC50
    1.02 μM
    Compound: Cidofovir
    Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 26001344]
    HEL EC50
    1.1 μM
    Compound: Cidofovir
    Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as reduction in virus-induced cytopathicity
    Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as reduction in virus-induced cytopathicity
    		[PMID: 22578783]
    HEL EC50
    1.2 μM
    Compound: (S)-CDV, HPMPC
    Antiviral activity against HCMV AD169/Davis infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days
    Antiviral activity against HCMV AD169/Davis infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days
    		[PMID: 21128666]
    HEL EC50
    1.2 μM
    Compound: Cidofovir
    Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 26001344]
    HEL EC50
    1.2 μM
    Compound: Cidofovir
    Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation
    Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation
    		[PMID: 27639368]
    HEL EC50
    1.33 μM
    Compound: Cidofovir
    Antiviral activity against HSV2 G infected in HEL cells by viral CPE assay
    Antiviral activity against HSV2 G infected in HEL cells by viral CPE assay
    		[PMID: 22858222]
    HEL EC50
    1.37 μM
    Compound: Cidofovir
    Antiviral activity against HCMV AD169 infected in HEL cells by viral CPE assay
    Antiviral activity against HCMV AD169 infected in HEL cells by viral CPE assay
    		[PMID: 22858222]
    HEL EC50
    1.4 μM
    Compound: Cidofovir
    Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 21232828]
    HEL EC50
    1.43 μM
    Compound: 2, (S)-HPMPC
    Antiviral activity against Human herpesvirus 2 G infected in HEL cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against Human herpesvirus 2 G infected in HEL cells assessed as protection against virus-induced cytopathicity
    		[PMID: 21565516]
    HEL EC50
    1.5 μM
    Compound: Cidofovir
    Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 23099097]
    HEL EC50
    1.5 μM
    Compound: Cidofovir
    Antiviral activity against thymidine kinase deficient and acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against thymidine kinase deficient and acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 23099097]
    HEL EC50
    1.5 μM
    Compound: Cidofovir
    Antiviral activity against Human herpesvirus 2 strain G infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    Antiviral activity against Human herpesvirus 2 strain G infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    		[PMID: 32214762]
    HEL EC50
    1.53 μg/mL
    Compound: (S)-HPMPC, cidofovir
    Antiviral activity against adenovirus 2 in HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against adenovirus 2 in HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 17298047]
    HEL EC50
    1.6 μM
    Compound: 2, (S)-HPMPC
    Antiviral activity against Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity
    		[PMID: 21565516]
    HEL EC50
    1.6 μM
    Compound: Cidofovir
    Antiviral activity against human cytomegalovirus AD169 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection
    Antiviral activity against human cytomegalovirus AD169 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection
    		[PMID: 19339082]
    HEL EC50
    1.74 μM
    Compound: HPMPC
    Antiviral activity against Cytomegalovirus AD169 infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity measured after 6 to 7 days
    Antiviral activity against Cytomegalovirus AD169 infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity measured after 6 to 7 days
    		[PMID: 32676147]
    HEL EC50
    1.75 μM
    Compound: Cidofovir
    Antiviral activity against thymidine kinase negative and ACV resistant HSV1 KOS infected in HEL cells by viral CPE assay
    Antiviral activity against thymidine kinase negative and ACV resistant HSV1 KOS infected in HEL cells by viral CPE assay
    		[PMID: 22858222]
    HEL EC50
    1.84 μM
    Compound: Cidofovir
    Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction of plaque formation
    Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction of plaque formation
    		[PMID: 23811093]
    HEL EC50
    10 μM
    Compound: Cidofovir
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    		10.1007/s00044-009-9248-y
    HEL EC50
    10 μM
    Compound: Cidofovir
    Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis
    Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis
    		[PMID: 21696963]
    HEL EC50
    10 μM
    Compound: Cidofovir
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
    		[PMID: 22459876]
    HEL EC50
    10 μM
    Compound: Cidofovir
    Antiviral activity against Vaccinia virus Lederle infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity
    Antiviral activity against Vaccinia virus Lederle infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity
    		[PMID: 23911856]
    HEL EC50
    10 μM
    Compound: Cidofovir
    Antiviral activity against Human adenovirus 2 infected in HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against Human adenovirus 2 infected in HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 27742238]
    HEL EC50
    10 μM
    Compound: Cidofovir
    Antiviral activity against Vaccinia virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    Antiviral activity against Vaccinia virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    		[PMID: 32214762]
    HEL EC50
    100 μM
    Compound: Cidofovir
    Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days
    Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days
    		[PMID: 19339082]
    HEL EC50
    10 μg/mL
    Compound: cidofovir
    Antiviral activity against Vaccinia virus infected in in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
    Antiviral activity against Vaccinia virus infected in in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
    		[PMID: 19419804]
    HEL EC50
    12.6 μg/mL
    Compound: Cidofovir
    Antiviral activity against thymidine kinase deficient Varicella Zoster Virus 07/1 infected in HEL cells assessed as reduction in virus plaque formation
    Antiviral activity against thymidine kinase deficient Varicella Zoster Virus 07/1 infected in HEL cells assessed as reduction in virus plaque formation
    		[PMID: 19324473]
    HEL EC50
    14 μM
    Compound: Cidofovir
    Antiviral activity against Vaccinia virus Lederie infected in HEL cells by viral CPE assay
    Antiviral activity against Vaccinia virus Lederie infected in HEL cells by viral CPE assay
    		[PMID: 22858222]
    HEL EC50
    17 μM
    Compound: Cidofovir
    Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 23811093]
    HEL EC50
    2 μM
    Compound: (S)-CDV, HPMPC
    Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days
    Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days
    		[PMID: 21128666]
    HEL EC50
    2 μM
    Compound: 2, (S)-HPMPC
    Antiviral activity against acyclovir-resistant Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against acyclovir-resistant Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity
    		[PMID: 21565516]
    HEL EC50
    2 μM
    Compound: CDF
    Antiviral activity against HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity
    		[PMID: 19281225]
    HEL EC50
    2 μM
    Compound: Cidofovir
    Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis
    Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis
    		[PMID: 21696963]
    HEL EC50
    2 μM
    Compound: Cidofovir
    Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis
    Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis
    		[PMID: 21696963]
    HEL EC50
    2 μM
    Compound: Cidofovir
    Antiviral activity against acyclovir-resistant TK-deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis
    Antiviral activity against acyclovir-resistant TK-deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis
    		[PMID: 21696963]
    HEL EC50
    2 μM
    Compound: Cidofovir
    Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
    Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
    		[PMID: 22459876]
    HEL EC50
    2 μM
    Compound: Cidofovir
    Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 23811093]
    HEL EC50
    2 μM
    Compound: Cidofovir
    Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 23811093]
    HEL EC50
    2 μM
    Compound: Cidofovir
    Antiviral activity against TK-negative Herpes simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against TK-negative Herpes simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 23811093]
    HEL EC50
    2 μM
    Compound: Cidofovir
    Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity
    Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity
    		[PMID: 23911856]
    HEL EC50
    2 μM
    Compound: Cidofovir
    Antiviral activity against thymidine kinase negative acyclovir positive Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity
    Antiviral activity against thymidine kinase negative acyclovir positive Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity
    		[PMID: 23911856]
    HEL EC50
    2.2 μg/mL
    Compound: (S)-HPMPC, cidofovir
    Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl cytosine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl cytosine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 18707089]
    HEL EC50
    2.5 μM
    Compound: (S)-CDV, HPMPC
    Antiviral activity against acyclovir-resistant thymidine kinase deficient HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days
    Antiviral activity against acyclovir-resistant thymidine kinase deficient HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days
    		[PMID: 21128666]
    HEL EC50
    2.6 μg/mL
    Compound: (S)-HPMPC, cidofovir
    Antiviral activity against vaccinia virus Lederle in HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against vaccinia virus Lederle in HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 17298047]
    HEL EC50
    20 μM
    Compound: CDF
    Antiviral activity against Vaccinia virus Lederle in human HEL cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against Vaccinia virus Lederle in human HEL cells assessed as protection against virus-induced cytopathicity
    		[PMID: 19281225]
    HEL EC50
    21 μM
    Compound: Cidofovir
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 23099097]
    HEL EC50
    22 μM
    Compound: Cidofovir
    Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis
    Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis
    		[PMID: 23603046]
    HEL EC50
    22 μM
    Compound: Cidofovir
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 26001344]
    HEL EC50
    25 μM
    Compound: Cidofovir
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 27742238]
    HEL EC50
    2 μg/mL
    Compound: Cidofovir
    Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    		[PMID: 18851889]
    HEL EC50
    2 μg/mL
    Compound: Cidofovir
    Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    		[PMID: 18851889]
    HEL EC50
    2 μg/mL
    Compound: Cidofovir
    Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
    Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
    		[PMID: 20724039]
    HEL EC50
    2 μg/mL
    Compound: Cidofovir
    Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
    Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
    		[PMID: 20724039]
    HEL EC50
    2 μg/mL
    Compound: HPMPC, cidofovir
    Antiviral activity against adenovirus type 2 in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against adenovirus type 2 in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17948980]
    HEL EC50
    3 μM
    Compound: Cidofovir
    Antiviral activity against Human herpesvirus 1 strain KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    Antiviral activity against Human herpesvirus 1 strain KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    		10.1007/s00044-009-9248-y
    HEL EC50
    3.09 μg/mL
    Compound: HPMPC, cidofovir
    Antiviral activity against vaccinia virus Lederle in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against vaccinia virus Lederle in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17948980]
    HEL EC50
    3.1 μM
    Compound: Cidofovir
    Antiviral activity against Cytomegalovirus AD-169 infected in human HEL cells assessed as reduction in virus plaque formation
    Antiviral activity against Cytomegalovirus AD-169 infected in human HEL cells assessed as reduction in virus plaque formation
    		[PMID: 23911856]
    HEL EC50
    3.1 μg/mL
    Compound: (S)-HPMPC, cidofovir
    Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl adenine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl adenine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 18707089]
    HEL EC50
    3.5 μM
    Compound: (S)-CDV, HPMPC
    Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days
    Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days
    		[PMID: 21128666]
    HEL EC50
    3 μg/mL
    Compound: Cidofovir
    Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    		[PMID: 18851889]
    HEL EC50
    3 μg/mL
    Compound: Cidofovir
    Antiviral activity against acyclovir-resistant TK deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
    Antiviral activity against acyclovir-resistant TK deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
    		[PMID: 20724039]
    HEL EC50
    3 μg/mL
    Compound: cidofovir
    Antiviral activity against HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
    Antiviral activity against HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
    		[PMID: 19419804]
    HEL EC50
    5 μM
    Compound: Cidofovir
    Antiviral activity against Human herpesvirus 2 strain G infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    Antiviral activity against Human herpesvirus 2 strain G infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    		10.1007/s00044-009-9248-y
    HEL EC50
    5 μM
    Compound: Cidofovir
    Antiviral activity against acyclovir-resistant TK-deficient Hepres simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    Antiviral activity against acyclovir-resistant TK-deficient Hepres simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    		10.1007/s00044-009-9248-y
    HEL EC50
    5 μM
    Compound: Cidofovir
    Antiviral activity against Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    Antiviral activity against Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    		[PMID: 32214762]
    HEL EC50
    5 μg/mL
    Compound: cidofovir
    Antiviral activity against HSV2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
    Antiviral activity against HSV2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
    		[PMID: 19419804]
    HEL EC50
    5 μg/mL
    Compound: cidofovir
    Antiviral activity against thymidine kinase-deficient ACV-resistant HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
    Antiviral activity against thymidine kinase-deficient ACV-resistant HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
    		[PMID: 19419804]
    HEL EC50
    6 μM
    Compound: (S)-CDV, HPMPC
    Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days
    Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days
    		[PMID: 21128666]
    HEL EC50
    6 μM
    Compound: Cidofovir
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 21232828]
    HEL EC50
    6 μM
    Compound: Cidofovir
    Antiviral activity against acyclovir-resistant thymidine kinase negative Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    Antiviral activity against acyclovir-resistant thymidine kinase negative Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    		[PMID: 32214762]
    HEL EC50
    7 μM
    Compound: 2, (S)-HPMPC
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection against virus-induced cytopathicity
    		[PMID: 21565516]
    HEL EC50
    7 μg/mL
    Compound: Cidofovir
    Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    		[PMID: 18851889]
    HEL EC50
    8 μg/mL
    Compound: Cidofovir
    Antiviral activity against Vaccinia virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
    Antiviral activity against Vaccinia virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
    		[PMID: 20724039]
    HEL EC50
    > 250 μM
    Compound: CDF
    Antiviral activity against VSV in human HEL cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against VSV in human HEL cells assessed as protection against virus-induced cytopathicity
    		[PMID: 19281225]
    HEL EC50
    > 250 μM
    Compound: Cidofovir
    Antiviral activity against Vesicular stomatitis virus infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    Antiviral activity against Vesicular stomatitis virus infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    		10.1007/s00044-009-9248-y
    HEL EC50
    > 250 μM
    Compound: Cidofovir
    Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
    Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
    		[PMID: 22459876]
    HEL EC50
    > 250 μM
    Compound: Cidofovir
    Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 23099097]
    HEL EC50
    > 250 μM
    Compound: Cidofovir
    Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 23811093]
    HEL EC50
    > 250 μM
    Compound: Cidofovir
    Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity
    Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity
    		[PMID: 23911856]
    HEL EC50
    > 250 μM
    Compound: Cidofovir
    Antiviral activity against Vesicular stomatitis virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    Antiviral activity against Vesicular stomatitis virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    		[PMID: 32214762]
    HEL EC50
    > 250 μg/mL
    Compound: Cidofovir
    Antiviral activity against VSV infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    Antiviral activity against VSV infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    		[PMID: 18851889]
    HEL EC50
    > 250 μg/mL
    Compound: Cidofovir
    Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
    Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
    		[PMID: 20724039]
    HEL EC50
    > 250 μg/mL
    Compound: Cidofovir
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    		[PMID: 20971531]
    HEL EC50
    > 250 μg/mL
    Compound: Cidofovir
    Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    		[PMID: 20971531]
    HEL EC50
    > 250 μg/mL
    Compound: Cidofovir
    Antiviral activity against thymidine kinase deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    Antiviral activity against thymidine kinase deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    		[PMID: 20971531]
    HEL EC50
    > 250 μg/mL
    Compound: cidofovir
    Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
    Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
    		[PMID: 19419804]
    HEL EC50
    > 31.5 μg/mL
    Compound: HPMPC, cidofovir
    Antiviral activity against VSV in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against VSV in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17948980]
    HEL IC50
    0.055 μg/mL
    Compound: (S)-HPMPC
    Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against TK- VZV strain 07/1
    Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against TK- VZV strain 07/1
    		10.1016/0960-894X(95)00278-2
    HEL IC50
    0.05 μg/mL
    Compound: (S)-HPMPC
    Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against TK- Varicella-Zoster virus (VZV) strain YS/R
    Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against TK- Varicella-Zoster virus (VZV) strain YS/R
    		10.1016/0960-894X(95)00278-2
    HEL IC50
    0.065 μg/mL
    Compound: (S)-HPMPC
    Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against TK+ VZV strain OKA
    Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against TK+ VZV strain OKA
    		10.1016/0960-894X(95)00278-2
    HEL IC50
    0.06 μg/mL
    Compound: (S)-HPMPC
    Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against cytomegalovirus (CMV) strain AD-169
    Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against cytomegalovirus (CMV) strain AD-169
    		10.1016/0960-894X(95)00278-2
    HEL IC50
    0.075 μg/mL
    Compound: (S)-HPMPC
    Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against cytomegalovirus (CMV) strain Davis
    Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against cytomegalovirus (CMV) strain Davis
    		10.1016/0960-894X(95)00278-2
    HEL IC50
    0.09 μg/mL
    Compound: (S)-HPMPC
    Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against TK+ Varicella-Zoster virus (VZV) strain YS
    Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against TK+ Varicella-Zoster virus (VZV) strain YS
    		10.1016/0960-894X(95)00278-2
    HEL 299 CC50
    192 μM
    Compound: 1a, HPMPC
    Cytotoxicity against HEL299 cells after 4 days by Z1 Coulter counting analysis
    Cytotoxicity against HEL299 cells after 4 days by Z1 Coulter counting analysis
    		[PMID: 17893157]
    HEL 299 EC50
    6.6 μM
    Compound: 1a, HPMPC
    Antiviral activity against Camelpox virus CML14 infected in HEL299 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining
    Antiviral activity against Camelpox virus CML14 infected in HEL299 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining
    		[PMID: 17893157]
    HEL 299 EC50
    8.2 μM
    Compound: 1a, HPMPC
    Antiviral activity against Camelpox virus CML1 infected in HEL299 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining
    Antiviral activity against Camelpox virus CML1 infected in HEL299 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining
    		[PMID: 17893157]
    HFF CC50
    100 μM
    Compound: cidofovir
    Cytotoxicity against HFF cells by alamar blue assay
    Cytotoxicity against HFF cells by alamar blue assay
    		[PMID: 17329103]
    HFF CC50
    > 100 μM
    Compound: 1, HPMPC, Vistide
    Cytotoxicity against HFF cells
    Cytotoxicity against HFF cells
    		[PMID: 21641218]
    HFF CC50
    > 100 μM
    Compound: CDV
    Cytotoxicity against HFF after 3 days by MTS assay
    Cytotoxicity against HFF after 3 days by MTS assay
    		[PMID: 19770274]
    HFF CC50
    > 100 μM
    Compound: Cidofovir
    Cytotoxicity against BK polyomavirus Gardner infected-human HFF cells assessed as reduction in cell viability after 7 days by cell titer-glo assay
    Cytotoxicity against BK polyomavirus Gardner infected-human HFF cells assessed as reduction in cell viability after 7 days by cell titer-glo assay
    		[PMID: 27624078]
    HFF CC50
    > 300 μM
    Compound: cidofovir
    Cytotoxicity against HFF cell line by neutral red toxicity assay
    Cytotoxicity against HFF cell line by neutral red toxicity assay
    		[PMID: 16722657]
    HFF CC50
    > 317 μM
    Compound: CDV
    Half-maximal cytotoxic concentration in human foreskin fibroblast (HFF) cells
    Half-maximal cytotoxic concentration in human foreskin fibroblast (HFF) cells
    		[PMID: 15828843]
    HFF CC50
    > 317 μM
    Compound: CDV
    Half-maximal cytotoxic concentration in human foreskin fibroblast (HFF) cells
    Half-maximal cytotoxic concentration in human foreskin fibroblast (HFF) cells
    		[PMID: 15828843]
    HFF CC50
    > 317 μM
    Compound: CDV
    Cytotoxicity against HFF cell
    Cytotoxicity against HFF cell
    		[PMID: 16539388]
    HFF CC50
    > 317 μM
    Compound: CDV
    Cytotoxicity against HFF cells
    Cytotoxicity against HFF cells
    		[PMID: 17116683]
    HFF CC50
    > 317 μM
    Compound: CDV
    Cytotoxicity against HFF cells after 7 days by neutral red assay
    Cytotoxicity against HFF cells after 7 days by neutral red assay
    		[PMID: 17724153]
    HFF CC50
    > 317 μM
    Compound: CDV
    Cytotoxicity against HFF cells after 7 days
    Cytotoxicity against HFF cells after 7 days
    		[PMID: 17846137]
    HFF CC50
    > 317 μM
    Compound: CDV
    Cytotoxicity against HFF after 7 days by neutral red uptake assay
    Cytotoxicity against HFF after 7 days by neutral red uptake assay
    		[PMID: 19029322]
    HFF CC50
    > 317 μM
    Compound: CDV
    Cytotoxicity against human HFF cells infected with Cowpox virus (Brighton Red) assessed as viable cells by neutral red uptake assay
    Cytotoxicity against human HFF cells infected with Cowpox virus (Brighton Red) assessed as viable cells by neutral red uptake assay
    		[PMID: 21376429]
    HFF CC50
    > 317 μM
    Compound: CDV
    Cytotoxicity against human HFF cells infected with Vaccinia virus Copenhagen assessed as viable cells by neutral red uptake assay
    Cytotoxicity against human HFF cells infected with Vaccinia virus Copenhagen assessed as viable cells by neutral red uptake assay
    		[PMID: 21376429]
    HFF CC50
    > 317 μM
    Compound: cidofovir
    Cytotoxicity against human HFF cells by neutral red uptake
    Cytotoxicity against human HFF cells by neutral red uptake
    		[PMID: 16603351]
    HFF CC50
    > 317 μM
    Compound: cidofovir
    Cytotoxicity against HFF cells by neutral red uptake assay
    Cytotoxicity against HFF cells by neutral red uptake assay
    		[PMID: 16821766]
    HFF EC50
    0.22 μM
    Compound: CDV
    Antiviral activity against Cytomegalovirus CMV T2211 infected in HFF cells by SEAP reporter gene assay
    Antiviral activity against Cytomegalovirus CMV T2211 infected in HFF cells by SEAP reporter gene assay
    		[PMID: 17709468]
    HFF EC50
    0.27 μM
    Compound: CDV
    Antiviral activity against Cytomegalovirus CMV T2258 with UL97 C592G mutant infected in HFF cells by SEAP reporter gene assay
    Antiviral activity against Cytomegalovirus CMV T2258 with UL97 C592G mutant infected in HFF cells by SEAP reporter gene assay
    		[PMID: 17709468]
    HFF EC50
    0.37 μM
    Compound: CDV
    Antiviral activity against Cytomegalovirus CMV T2798 with pol T813S UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay
    Antiviral activity against Cytomegalovirus CMV T2798 with pol T813S UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay
    		[PMID: 17709468]
    HFF EC50
    0.42 μM
    Compound: CDV
    Antiviral activity against Cytomegalovirus CMV T2417 with pol A809V mutant infected in HFF cells by SEAP reporter gene assay
    Antiviral activity against Cytomegalovirus CMV T2417 with pol A809V mutant infected in HFF cells by SEAP reporter gene assay
    		[PMID: 17709468]
    HFF EC50
    0.45 μM
    Compound: CDV
    Antiviral activity against Cytomegalovirus CMV T2784 with pol A809V UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay
    Antiviral activity against Cytomegalovirus CMV T2784 with pol A809V UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay
    		[PMID: 17709468]
    HFF EC50
    0.58 μM
    Compound: CDV
    Antiviral activity against Cytomegalovirus CMV T2420 with pol G841A mutant infected in HFF cells by SEAP reporter gene assay
    Antiviral activity against Cytomegalovirus CMV T2420 with pol G841A mutant infected in HFF cells by SEAP reporter gene assay
    		[PMID: 17709468]
    HFF EC50
    0.6 μM
    Compound: CDV
    Antiviral activity against Cytomegalovirus CMV T2542 with pol T813S mutant infected in HFF cells by SEAP reporter gene assay
    Antiviral activity against Cytomegalovirus CMV T2542 with pol T813S mutant infected in HFF cells by SEAP reporter gene assay
    		[PMID: 17709468]
    HFF EC50
    0.67 μM
    Compound: CDV
    Antiviral activity against Cytomegalovirus CMV 2817 with pol G841A UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay
    Antiviral activity against Cytomegalovirus CMV 2817 with pol G841A UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay
    		[PMID: 17709468]
    HFF EC50
    1.1 μM
    Compound: Cidofovir
    Antiviral activity against BK polyomavirus Gardner infected in human HFF cells assessed as reduction in DNA copy number after 7 days by PCR analysis
    Antiviral activity against BK polyomavirus Gardner infected in human HFF cells assessed as reduction in DNA copy number after 7 days by PCR analysis
    		[PMID: 27624078]
    HFF EC50
    1.2 μM
    Compound: 2, (S)-HPMPC
    Antiviral activity against Human cytomegalovirus AD169 infected in HFF cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against Human cytomegalovirus AD169 infected in HFF cells assessed as protection against virus-induced cytopathicity
    		[PMID: 21565516]
    HFF EC50
    10 μM
    Compound: CDV, cidofovir
    Antiviral activity against TK+ Cowpox virus Delta crmA in HFF cells after 48 hrs by beta-galactosidase assay
    Antiviral activity against TK+ Cowpox virus Delta crmA in HFF cells after 48 hrs by beta-galactosidase assay
    		[PMID: 17325220]
    HFF EC50
    11 μM
    Compound: CDV, cidofovir
    Antiviral activity against Vaccinia virus in HFF cells after 1 hr by plaque reduction assay
    Antiviral activity against Vaccinia virus in HFF cells after 1 hr by plaque reduction assay
    		[PMID: 17325220]
    HFF EC50
    16 μM
    Compound: CDV, cidofovir
    Antiviral activity against TK- Cowpox virus TK:GFP lacZ in HFF cells after 48 hrs by beta-galactosidase assay
    Antiviral activity against TK- Cowpox virus TK:GFP lacZ in HFF cells after 48 hrs by beta-galactosidase assay
    		[PMID: 17325220]
    HFF EC50
    20 μM
    Compound: cidofovir
    Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction in plaque formation
    Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction in plaque formation
    		[PMID: 16603351]
    HFF EC50
    24 μM
    Compound: cidofovir
    Antiviral activity against vaccinia virus in HFF cells by plaque reduction assay
    Antiviral activity against vaccinia virus in HFF cells by plaque reduction assay
    		[PMID: 16821766]
    HFF EC50
    25.3 μM
    Compound: CDV
    Antiviral activity against Vaccinia virus Copenhagen replication in HFF cells
    Antiviral activity against Vaccinia virus Copenhagen replication in HFF cells
    		[PMID: 16539388]
    HFF EC50
    26 μM
    Compound: CDV
    Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction of viral replication after 3 days
    Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction of viral replication after 3 days
    		[PMID: 17846137]
    HFF EC50
    27 μM
    Compound: CDV
    Effective concentration required to inhibit vaccinia virus plaque formation in human foreskin fibroblast (HFF) cells
    Effective concentration required to inhibit vaccinia virus plaque formation in human foreskin fibroblast (HFF) cells
    		[PMID: 15828843]
    HFF EC50
    29 μM
    Compound: CDV
    Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction of viral replication after 3 days
    Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction of viral replication after 3 days
    		[PMID: 17846137]
    HFF EC50
    29.2 μM
    Compound: CDV
    Antiviral activity against Vaccinia virus Copenhagen infected HFF cells
    Antiviral activity against Vaccinia virus Copenhagen infected HFF cells
    		[PMID: 17116683]
    HFF EC50
    29.2 μM
    Compound: CDV
    Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction plaque formation after 3 days
    Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction plaque formation after 3 days
    		[PMID: 17724153]
    HFF EC50
    3.2 μM
    Compound: cidofovir
    Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction in cytopathogenicity
    Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction in cytopathogenicity
    		[PMID: 16603351]
    HFF EC50
    3.2 μM
    Compound: cidofovir
    Antiviral activity against vaccinia virus in HFF cells by cytopathogenic effect assay
    Antiviral activity against vaccinia virus in HFF cells by cytopathogenic effect assay
    		[PMID: 16821766]
    HFF EC50
    3.3 μM
    Compound: cidofovir
    Antiviral activity against TK+ cowpox virus delta crmA in HFF cells
    Antiviral activity against TK+ cowpox virus delta crmA in HFF cells
    		[PMID: 16821766]
    HFF EC50
    30.7 μM
    Compound: CDV
    Antiviral activity against Cowpox virus Brighton replication in HFF cells
    Antiviral activity against Cowpox virus Brighton replication in HFF cells
    		[PMID: 16539388]
    HFF EC50
    32 μM
    Compound: CDV, cidofovir
    Antiviral activity against Cowpox virus Brighton in HFF cells after 1 hr by plaque reduction assay
    Antiviral activity against Cowpox virus Brighton in HFF cells after 1 hr by plaque reduction assay
    		[PMID: 17325220]
    HFF EC50
    32 μM
    Compound: cidofovir
    Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction in plaque formation
    Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction in plaque formation
    		[PMID: 16603351]
    HFF EC50
    33 μM
    Compound: CDV
    Antiviral activity against Vaccinia virus WR infected HFF cells
    Antiviral activity against Vaccinia virus WR infected HFF cells
    		[PMID: 17116683]
    HFF EC50
    33 μM
    Compound: CDV
    Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction plaque formation after 3 days
    Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction plaque formation after 3 days
    		[PMID: 17724153]
    HFF EC50
    35 μM
    Compound: CDV
    Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction of viral replication after 3 days
    Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction of viral replication after 3 days
    		[PMID: 17846137]
    HFF EC50
    38 μM
    Compound: CDV
    Effective concentration required to inhibit cowpox virus plaque formation in human foreskin fibroblast (HFF) cells
    Effective concentration required to inhibit cowpox virus plaque formation in human foreskin fibroblast (HFF) cells
    		[PMID: 15828843]
    HFF EC50
    4.8 μM
    Compound: cidofovir
    Antiviral activity against Vaccinia virus in HFF cells
    Antiviral activity against Vaccinia virus in HFF cells
    		[PMID: 16275078]
    HFF EC50
    40 μM
    Compound: cidofovir
    Antiviral activity against cowpox virus in HFF cells by plaque reduction assay
    Antiviral activity against cowpox virus in HFF cells by plaque reduction assay
    		[PMID: 16821766]
    HFF EC50
    41.1 μM
    Compound: CDV
    Antiviral activity against Cowpox virus Brighton infected HFF cells
    Antiviral activity against Cowpox virus Brighton infected HFF cells
    		[PMID: 17116683]
    HFF EC50
    41.1 μM
    Compound: CDV
    Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction plaque formation after 3 days
    Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction plaque formation after 3 days
    		[PMID: 17724153]
    HFF EC50
    5 μM
    Compound: cidofovir
    Antiviral activity against Cowpox virus in HFF cells
    Antiviral activity against Cowpox virus in HFF cells
    		[PMID: 16275078]
    HFF EC50
    5.2 μM
    Compound: cidofovir
    Antiviral activity against TK- cowpox virus TK:GFP lacZ in HFF cells
    Antiviral activity against TK- cowpox virus TK:GFP lacZ in HFF cells
    		[PMID: 16821766]
    HFF EC50
    6.7 μM
    Compound: CDV
    Antiviral activity against Cowpox virus (Brighton Red) infected in human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay
    Antiviral activity against Cowpox virus (Brighton Red) infected in human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay
    		[PMID: 21376429]
    HFF EC50
    6.9 μM
    Compound: cidofovir
    Antiviral activity against vaccinia virus Copenhagen measured as cytopathogenicity in HFF cells
    Antiviral activity against vaccinia virus Copenhagen measured as cytopathogenicity in HFF cells
    		[PMID: 16722657]
    HFF EC50
    7.1 μM
    Compound: cidofovir
    Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction in cytopathogenicity
    Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction in cytopathogenicity
    		[PMID: 16603351]
    HFF EC50
    8.3 μM
    Compound: cidofovir
    Antiviral activity against cowpox virus Brighton measured as cytopathogenicity in HFF cells
    Antiviral activity against cowpox virus Brighton measured as cytopathogenicity in HFF cells
    		[PMID: 16722657]
    HFF EC50
    9 μM
    Compound: cidofovir
    Antiviral activity against cowpox virus Brighton by plaque reduction in HFF cells
    Antiviral activity against cowpox virus Brighton by plaque reduction in HFF cells
    		[PMID: 16722657]
    HFF EC50
    9 μM
    Compound: cidofovir
    Antiviral activity against vaccinia virus Copenhagen assessed as plaque reduction in HFF cells
    Antiviral activity against vaccinia virus Copenhagen assessed as plaque reduction in HFF cells
    		[PMID: 16722657]
    HFF EC50
    9.8 μM
    Compound: CDV
    Antiviral activity against Vaccinia virus Copenhagen infected in human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay
    Antiviral activity against Vaccinia virus Copenhagen infected in human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay
    		[PMID: 21376429]
    HFF IC50
    0.11 μM
    Compound: 1, HPMPC, Vistide
    Antiviral activity against Human cytomegalovirus Towne infected in HFF cells assessed as reduction in plaque formation after 10 days
    Antiviral activity against Human cytomegalovirus Towne infected in HFF cells assessed as reduction in plaque formation after 10 days
    		[PMID: 21641218]
    HFF IC50
    0.2 μM
    Compound: CDV
    Antiviral activity against Human CMV T2211 in HFF cells by SEAP assay
    Antiviral activity against Human CMV T2211 in HFF cells by SEAP assay
    		[PMID: 17043128]
    HFF IC50
    0.28 μM
    Compound: 2, (S)-HPMPC, Cidofovir, CDV
    Antiviral activity against HCMV Towne infected in HFF cells incubated for 10 days by plaque reduction assay
    Antiviral activity against HCMV Towne infected in HFF cells incubated for 10 days by plaque reduction assay
    		[PMID: 21812420]
    HFF IC50
    0.3 μM
    Compound: CDV
    Antiviral activity against Human CMV T2233 in HFF cells by SEAP assay
    Antiviral activity against Human CMV T2233 in HFF cells by SEAP assay
    		[PMID: 17043128]
    HFF IC50
    0.3 μM
    Compound: CDV
    Antiviral activity against Human CMV T2241 in HFF cells by SEAP assay
    Antiviral activity against Human CMV T2241 in HFF cells by SEAP assay
    		[PMID: 17043128]
    HFF IC50
    0.35 μM
    Compound: cidofovir
    Antiviral activity against HCMV infected HFF cells after 5 days by dot blot assay
    Antiviral activity against HCMV infected HFF cells after 5 days by dot blot assay
    		[PMID: 17329103]
    HFF IC50
    0.7 μM
    Compound: CDV
    Antiviral activity against Human CMV T2291 in HFF cells by SEAP assay
    Antiviral activity against Human CMV T2291 in HFF cells by SEAP assay
    		[PMID: 17043128]
    HFF IC50
    0.9 μM
    Compound: CDV
    Antiviral activity against Human CMV AD169 in HFF cells by PRA
    Antiviral activity against Human CMV AD169 in HFF cells by PRA
    		[PMID: 17043128]
    HFF IC50
    1.9 μM
    Compound: CDV
    Antiproliferative activity against HFF after 3 days by coulter counter assay
    Antiproliferative activity against HFF after 3 days by coulter counter assay
    		[PMID: 19029322]
    HFF IC50
    1.9 μM
    Compound: CDV
    Antiproliferative activity against HFF after 3 days by Coulter counting analysis
    Antiproliferative activity against HFF after 3 days by Coulter counting analysis
    		[PMID: 19770274]
    HFF IC50
    100 μM
    Compound: 2, (S)-HPMPC, Cidofovir, CDV
    Cytotoxicity against HFF cells after 48 hrs by visual cytotoxicity observation assay
    Cytotoxicity against HFF cells after 48 hrs by visual cytotoxicity observation assay
    		[PMID: 21812420]
    HFF IC50
    20 μM
    Compound: 1, HPMPC, Vistide
    Antiviral activity against Vaccinia virus Copenhagen infected in HFF cells assessed as reduction in plaque formation after 3 days
    Antiviral activity against Vaccinia virus Copenhagen infected in HFF cells assessed as reduction in plaque formation after 3 days
    		[PMID: 21641218]
    HFF IC50
    20 μM
    Compound: 2, (S)-HPMPC, Cidofovir, CDV
    Antiviral activity against Vaccinia virus Copenhagen infected in HFF cells incubated for 3 days by plaque reduction assay
    Antiviral activity against Vaccinia virus Copenhagen infected in HFF cells incubated for 3 days by plaque reduction assay
    		[PMID: 21812420]
    HFF IC50
    3.3 μM
    Compound: CDV
    Antiviral activity against Human CMV T2291 in HFF cells by PRA
    Antiviral activity against Human CMV T2291 in HFF cells by PRA
    		[PMID: 17043128]
    HFF IC50
    30 μM
    Compound: 1, HPMPC, Vistide
    Antiviral activity against Cowpox virus Brighton infected in HFF cells assessed as reduction in plaque formation after 3 days
    Antiviral activity against Cowpox virus Brighton infected in HFF cells assessed as reduction in plaque formation after 3 days
    		[PMID: 21641218]
    HFF IC50
    30 μM
    Compound: 2, (S)-HPMPC, Cidofovir, CDV
    Antiviral activity against Cowpox virus Brighton infected in HFF cells incubated for 3 days by plaque reduction assay
    Antiviral activity against Cowpox virus Brighton infected in HFF cells incubated for 3 days by plaque reduction assay
    		[PMID: 21812420]
    HFF IC50
    4.7 μM
    Compound: CDV
    Antiviral activity against Human CMV T2311 in HFF cells by SEAP assay
    Antiviral activity against Human CMV T2311 in HFF cells by SEAP assay
    		[PMID: 17043128]
    HFF IC50
    4.9 μM
    Compound: CDV
    Antiviral activity against Human CMV T2293 in HFF cells by PRA
    Antiviral activity against Human CMV T2293 in HFF cells by PRA
    		[PMID: 17043128]
    HFF IC50
    5.2 μM
    Compound: CDV
    Antiviral activity against Human CMV T2293 in HFF cells by SEAP assay
    Antiviral activity against Human CMV T2293 in HFF cells by SEAP assay
    		[PMID: 17043128]
    HFF IC50
    8.9 μM
    Compound: CDV
    Antiviral activity against Human CMV T2311 in HFF cells by PRA
    Antiviral activity against Human CMV T2311 in HFF cells by PRA
    		[PMID: 17043128]
    HFF IC50
    > 100 μM
    Compound: cdv
    Cytotoxicity against HFF cells
    Cytotoxicity against HFF cells
    		[PMID: 16814545]
    HT-3 EC50
    > 100000 nM
    Compound: Cidofovir
    Antiproliferative activity against HPV-non-transformed human HT3 cells after 7 days by SRB assay
    Antiproliferative activity against HPV-non-transformed human HT3 cells after 7 days by SRB assay
    		[PMID: 19398642]
    HeLa CC50
    244 μg/mL
    Compound: Cidofovir
    Cytotoxicity against Varicella Zoster Virus infected human HeLa cells assessed as reduction in cell growth
    Cytotoxicity against Varicella Zoster Virus infected human HeLa cells assessed as reduction in cell growth
    		[PMID: 19324473]
    HeLa CC50
    50.8 μM
    Compound: Cidofovir
    Cytotoxicity against human HeLa cells assessed as cell viability by colorimetric formazan-based MTS assay
    Cytotoxicity against human HeLa cells assessed as cell viability by colorimetric formazan-based MTS assay
    		[PMID: 22459876]
    HeLa CC50
    > 50 μg/mL
    Compound: Cidofovir
    Cytotoxicity against Varicella Zoster Virus infected human HeLa cells assessed as change in cell morphology
    Cytotoxicity against Varicella Zoster Virus infected human HeLa cells assessed as change in cell morphology
    		[PMID: 19324473]
    HeLa EC50
    > 100000 nM
    Compound: Cidofovir
    Antiproliferative activity against HPV-transformed human HeLa cells after 7 days by SRB assay
    Antiproliferative activity against HPV-transformed human HeLa cells after 7 days by SRB assay
    		[PMID: 19398642]
    HeLa EC50
    > 31.5 μg/mL
    Compound: HPMPC, cidofovir
    Antiviral activity against Coxsackie virus B4 in HeLa cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against Coxsackie virus B4 in HeLa cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17948980]
    HeLa EC50
    > 31.5 μg/mL
    Compound: HPMPC, cidofovir
    Antiviral activity against RSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against RSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17948980]
    HeLa EC50
    > 31.5 μg/mL
    Compound: HPMPC, cidofovir
    Antiviral activity against VSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against VSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17948980]
    HeLa S3 EC50
    18.74 μM
    Compound: Cidofovir
    Antiviral activity against Vaccinia virus IHD-J ATCC VR-156 infected in HeLaS3 cells after 3 to 5 days by plaque assay
    Antiviral activity against Vaccinia virus IHD-J ATCC VR-156 infected in HeLaS3 cells after 3 to 5 days by plaque assay
    		[PMID: 18852271]
    HeLa S3 EC50
    20.61 μM
    Compound: Cidofovir
    Antiviral activity against Vaccinia virus IHD-W ATCC VR-1441 infected in HeLaS3 cells after 3 to 5 days by plaque assay
    Antiviral activity against Vaccinia virus IHD-W ATCC VR-1441 infected in HeLaS3 cells after 3 to 5 days by plaque assay
    		[PMID: 18852271]
    HeLa S3 EC50
    30.85 μM
    Compound: Cidofovir
    Antiviral activity against Vaccinia virus WR harboring the HIV gag gene infected in HeLaS3 cells after 3 to 5 days by plaque assay
    Antiviral activity against Vaccinia virus WR harboring the HIV gag gene infected in HeLaS3 cells after 3 to 5 days by plaque assay
    		[PMID: 18852271]
    HeLa S3 IC50
    38 μM
    Compound: Cidofovir
    Antiviral activity against Vaccinia virus WR harboring the HIV gag gene infected in HeLaS3 cells assessed as inhibition of viral replication in hollow-fiber infection model by plaque assay
    Antiviral activity against Vaccinia virus WR harboring the HIV gag gene infected in HeLaS3 cells assessed as inhibition of viral replication in hollow-fiber infection model by plaque assay
    		[PMID: 18852271]
    Jurkat CC50
    100 μM
    Compound: cidofovir
    Cytotoxicity against human Jurkat cells by alamar blue assay
    Cytotoxicity against human Jurkat cells by alamar blue assay
    		[PMID: 17329103]
    Jurkat IC50
    100 μM
    Compound: cdv
    Cytotoxicity against human Jurkat cells
    Cytotoxicity against human Jurkat cells
    		[PMID: 16814545]
    KB CC50
    > 100 μM
    Compound: 1, HPMPC, Vistide
    Cytotoxicity against human KB cells after 48 hrs by crystal violet staining technique
    Cytotoxicity against human KB cells after 48 hrs by crystal violet staining technique
    		[PMID: 21641218]
    KB IC50
    > 100 μM
    Compound: 2, (S)-HPMPC, Cidofovir, CDV
    Cytotoxicity against human KB cells after 48 hrs by crystal violet staining based spectrophotometric analysis
    Cytotoxicity against human KB cells after 48 hrs by crystal violet staining based spectrophotometric analysis
    		[PMID: 21812420]
    ME-180 EC50
    64700 nM
    Compound: Cidofovir
    Antiproliferative activity against HPV-transformed human ME180 cells after 7 days by SRB assay
    Antiproliferative activity against HPV-transformed human ME180 cells after 7 days by SRB assay
    		[PMID: 19398642]
    MOLT-3 EC50
    2.1 μg/mL
    Compound: HPMPC, cidofovir
    Antiviral activity against HHV6B strain Z29 in MOLT3 cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against HHV6B strain Z29 in MOLT3 cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17948980]
    MRC5 CC50
    19 μg/mL
    Compound: HPMPC
    Compound was tested for cytotoxicity by measuring inhibition of MRC-5 cell proliferation.
    Compound was tested for cytotoxicity by measuring inhibition of MRC-5 cell proliferation.
    		[PMID: 9934471]
    MRC5 IC50
    0.04 μg/mL
    Compound: HPMPC
    Compound was tested for cytotoxicity by measuring inhibition of MRC-5 cell proliferation.
    Compound was tested for cytotoxicity by measuring inhibition of MRC-5 cell proliferation.
    		[PMID: 9934471]
    MRC5 IC50
    0.3 μM
    Compound: CDV
    Antiviral activity against Human CMV Towne in MRC5 cells by PRA
    Antiviral activity against Human CMV Towne in MRC5 cells by PRA
    		[PMID: 17043128]
    MRC5 IC50
    0.6 μM
    Compound: CDV
    Antiviral activity against Human CMV T2296 in MRC5 cells by PRA
    Antiviral activity against Human CMV T2296 in MRC5 cells by PRA
    		[PMID: 17043128]
    MRC5 IC50
    1.8 μM
    Compound: CDV
    Antiviral activity against Human CMV T2287 in MRC5 cells by PRA
    Antiviral activity against Human CMV T2287 in MRC5 cells by PRA
    		[PMID: 17043128]
    MRC5 IC50
    10 μM
    Compound: HPMPC
    Inhibitory activity against cytopathic effect of HSV-2(E 194) in MRC-5 cells
    Inhibitory activity against cytopathic effect of HSV-2(E 194) in MRC-5 cells
    		[PMID: 8632439]
    NHDF CC50
    200 μM
    Compound: HPMPC
    Cytotoxic activity against NHDF cell growth
    Cytotoxic activity against NHDF cell growth
    		[PMID: 8632439]
    NHDF IC50
    0.5 μM
    Compound: HPMPC
    Inhibitory activity against replication of HCMV in NHDF cells
    Inhibitory activity against replication of HCMV in NHDF cells
    		[PMID: 8632439]
    Osteoclast-like IC50
    10 μM
    Compound: cdv
    Cytotoxicity against human bone marrow cells assessed as inhibition of colony forming unit of granulocyte/macrophage
    Cytotoxicity against human bone marrow cells assessed as inhibition of colony forming unit of granulocyte/macrophage
    		[PMID: 16814545]
    SCC-4 EC50
    > 100000 nM
    Compound: Cidofovir
    Antiproliferative activity against HPV-non-transformed human SCC4 cells after 7 days by SRB assay
    Antiproliferative activity against HPV-non-transformed human SCC4 cells after 7 days by SRB assay
    		[PMID: 19398642]
    SCC-9 EC50
    > 100000 nM
    Compound: Cidofovir
    Antiproliferative activity against HPV-non-transformed human SCC9 cells after 7 days by SRB assay
    Antiproliferative activity against HPV-non-transformed human SCC9 cells after 7 days by SRB assay
    		[PMID: 19398642]
    SiHa EC50
    > 100000 nM
    Compound: Cidofovir
    Antiproliferative activity against HPV-transformed human SiHa cells after 7 days by SRB assay
    Antiproliferative activity against HPV-transformed human SiHa cells after 7 days by SRB assay
    		[PMID: 19398642]
    Vero CC50
    475.3 μM
    Compound: CDV
    Cytotoxicity against African green monkey Vero cells assessed as reduction in cell death
    Cytotoxicity against African green monkey Vero cells assessed as reduction in cell death
    		[PMID: 33479623]
    Vero CC50
    475.3 μM
    Compound: Cidofovir
    Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 4 days by neural red dye-based spectrophotometric method
    Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 4 days by neural red dye-based spectrophotometric method
    		[PMID: 30746065]
    Vero CC50
    989.25 μM
    Compound: Cidofovir
    Cytotoxicity against African green monkey Vero cells measured after 4 days by colorimetric assay
    Cytotoxicity against African green monkey Vero cells measured after 4 days by colorimetric assay
    		[PMID: 36414175]
    Vero CC50
    > 720 μM
    Compound: CFV
    Cytotoxicity against african green monkey Vero cells after 2 days
    Cytotoxicity against african green monkey Vero cells after 2 days
    		[PMID: 17438061]
    Vero EC50
    14.4 μM
    Compound: CFV
    Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs
    Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs
    		[PMID: 17438061]
    Vero EC50
    21.6 μM
    Compound: CFV
    Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs
    Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs
    		[PMID: 17438061]
    Vero EC50
    28.9 μM
    Compound: CFV
    Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs
    Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs
    		[PMID: 17438061]
    Vero EC50
    > 31.5 μg/mL
    Compound: HPMPC, cidofovir
    Antiviral activity against Coxsackie virus B4 in Vero cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against Coxsackie virus B4 in Vero cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17948980]
    Vero EC50
    > 31.5 μg/mL
    Compound: HPMPC, cidofovir
    Antiviral activity against Parainfluenza 3 in Vero cells reduction of virus-induced cytopathogenicity after 4 days
    Antiviral activity against Parainfluenza 3 in Vero cells reduction of virus-induced cytopathogenicity after 4 days
    		[PMID: 17948980]
    Vero EC50
    > 31.5 μg/mL
    Compound: HPMPC, cidofovir
    Antiviral activity against Punta Toro virus in Vero cells reduction of virus-induced cytopathogenicity after 4 days
    Antiviral activity against Punta Toro virus in Vero cells reduction of virus-induced cytopathogenicity after 4 days
    		[PMID: 17948980]
    Vero EC50
    > 31.5 μg/mL
    Compound: HPMPC, cidofovir
    Antiviral activity against Reovirus 1 in Vero cells reduction of virus-induced cytopathogenicity after 4 days
    Antiviral activity against Reovirus 1 in Vero cells reduction of virus-induced cytopathogenicity after 4 days
    		[PMID: 17948980]
    Vero EC50
    > 31.5 μg/mL
    Compound: HPMPC, cidofovir
    Antiviral activity against Sindbis virus in Vero cells reduction of virus-induced cytopathogenicity after 4 days
    Antiviral activity against Sindbis virus in Vero cells reduction of virus-induced cytopathogenicity after 4 days
    		[PMID: 17948980]
    Vero IC50
    1.276 μg/mL
    Compound: cidofovir
    Compound concentration to reduce virus cytopathic effect by 50% tested against herpes simplex virus-1(G) using Vero cell line
    Compound concentration to reduce virus cytopathic effect by 50% tested against herpes simplex virus-1(G) using Vero cell line
    		[PMID: 15745823]
    Vero IC50
    3.937 μg/mL
    Compound: cidofovir
    Compound concentration to reduce virus cytopathic effect by 50% tested against herpes simplex virus-1(KOS) using Vero cell line
    Compound concentration to reduce virus cytopathic effect by 50% tested against herpes simplex virus-1(KOS) using Vero cell line
    		[PMID: 15745823]
    Vero IC50
    40 μM
    Compound: Cidofovir
    Antiviral activity against Vaccinia virus Copenhagen infected in African green monkey Vero cells assessed as inhibition of viral replication after 4 days by neural red dye-based spectrophotometric method
    Antiviral activity against Vaccinia virus Copenhagen infected in African green monkey Vero cells assessed as inhibition of viral replication after 4 days by neural red dye-based spectrophotometric method
    		[PMID: 30746065]
    Vero 76 CC50
    > 100 μM
    Compound: CDF
    Cytotoxicity against mock-infected African green monkey Vero 76 cells assessed as reduction in proliferation after 48 to 96 hrs by MTT method
    Cytotoxicity against mock-infected African green monkey Vero 76 cells assessed as reduction in proliferation after 48 to 96 hrs by MTT method
    		[PMID: 25014745]
    Vero 76 EC50
    19 μM
    Compound: CDF
    Antiviral activity against Vaccinia virus Lister ATCC VR-1549 infected in Vero 76 cells after 3 days by plaque reduction assays
    Antiviral activity against Vaccinia virus Lister ATCC VR-1549 infected in Vero 76 cells after 3 days by plaque reduction assays
    		[PMID: 25014745]
    Vero 76 EC50
    19 μM
    Compound: CDF
    Antiviral activity against VV Elstree ATCC VR-1549 infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay
    Antiviral activity against VV Elstree ATCC VR-1549 infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay
    		[PMID: 26479028]
    Vero 76 EC50
    > 100 μM
    Compound: CDF
    Antiviral activity against CVB-5 virus Faulkner ATCC VR-185 infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay
    Antiviral activity against CVB-5 virus Faulkner ATCC VR-185 infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay
    		[PMID: 26479028]
    Vero C1008 IC50
    1.8 μM
    Compound: Cidofovir
    Antiviral activity against HSV-1 L2/Rp-ACV/2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect
    Antiviral activity against HSV-1 L2/Rp-ACV/2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect
    		[PMID: 28408228]
    Vero C1008 IC50
    111.9 μM
    Compound: Cidofovir
    Antiviral activity against acyclovir and cidofovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect
    Antiviral activity against acyclovir and cidofovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect
    		[PMID: 28408228]
    Vero C1008 IC50
    14 μM
    Compound: Cidofovir
    Antiviral activity against HSV1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect
    Antiviral activity against HSV1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect
    		[PMID: 28408228]
    Vero C1008 IC50
    14 μM
    Compound: Cidofovir
    Antiviral activity against acyclovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect
    Antiviral activity against acyclovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect
    		[PMID: 28408228]
    Vero C1008 IC50
    27.9 μM
    Compound: Cidofovir
    Antiviral activity against foscarnet-resistant HSV-1 F+ infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect
    Antiviral activity against foscarnet-resistant HSV-1 F+ infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect
    		[PMID: 28408228]
    Vero C1008 IC50
    7 μM
    Compound: Cidofovir
    Antiviral activity against acyclovir and foscarnet-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect
    Antiviral activity against acyclovir and foscarnet-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect
    		[PMID: 28408228]
    WI-38 CC50
    10 μg/mL
    Compound: HPMPC
    Compound was tested for antiviral activity against WI-38 cell line using a plaque reduction assay; 10-50
    Compound was tested for antiviral activity against WI-38 cell line using a plaque reduction assay; 10-50
    		[PMID: 9934471]
    WI-38 IC50
    0.1 μg/mL
    Compound: HPMPC
    Compound was tested for antiviral activity against WI-38 cell line using a plaque reduction assay; 0.1-1
    Compound was tested for antiviral activity against WI-38 cell line using a plaque reduction assay; 0.1-1
    		[PMID: 9934471]
    In Vitro

    Cidofovir (5-100 μM, 72 hours) dihydrate has antiviral activity against feline herpesvirus type-1 (FHV-1) with an IC50 of 11 μM, and can reduce Crandell-Reese feline kidney cells counts in a dose dependent manner[1].
    Cidofovir (10-1000 μM, 24-120 hours) dihydrate can reduce cancer cell viability and induces apoptosis[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Cidofovir dihydrate Related Antibodies

    Cell Cytotoxicity Assay[1]

    Cell Line: Crandell-Reese feline kidney(CRFK) cells
    Concentration: 10-100 μM
    Incubation Time: 72 hours
    Result: Reduced CRFK cells by 9.1%.

    Cell Viability Assay[3]

    Cell Line: Caco-2, FTC-133, HeLa, Hep-G2, MDA-MB-231, NCI-H1975 and PC-3 cells
    Concentration: 10-1000 μM
    Incubation Time: 24, 48, 72, 96, 120 hours
    Result: Resulted in a gradual decrease in tumor cell viability with time and concentration increasing and inhibited the number of FTC-133 cell clones by about 55% at 100 μM comparing to the untreated group.

    Apoptosis Analysis[3]

    Cell Line: FTC-133 cells
    Concentration: 100 μM
    Incubation Time: 96 hours
    Result: Showed a significant increase in the expression of pro-apoptotic proteins, such as cytochrome c, phospho-p53 (S15) and caspase-3 by 130%, 49%, and 46%, respectively while the anti-apoptotic protein Bcl-x decreased significantly by 57% comparing to the untreated cells.
    In Vivo

    Cidofovir (subcutaneous injection, 100 mg/kg, 3-6 days interval, 21 days) dihydrate is highly protective against death from cowpox virus (CPV) infection at high doses in female weanling BALB/c mice[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Female weanling BALB/c mice infected with cowpox virus (CPV)[2]
    Dosage: 100 mg/kg
    Administration: Subcutaneous injection; 3-6 days interval; 21 days
    Result: Prevented 80-100% of mouse deaths when administered on the first 4-3 days before infection.
    Protected 35-50% of mice when administered on the fourth day after infection, and 10-20% when administered on the sixth day.
    Clinical Trial
    Molecular Weight

    315.22

    Formula

    C8H18N3O8P
    CAS No.
    SMILES

    OC[C@@H](OCP(O)(O)=O)CN1C=CC(N)=NC1=O.O.O
    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    Please store the product under the recommended conditions in the Certificate of Analysis.
    Purity & Documentation
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Cidofovir dihydrate Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Cidofovir dihydrate149394-66-1GS 0504 dihydrate HPMPC dihydrate (S)-HPMPC dihydrateCMVDNA/RNA SynthesisOrthopoxvirusApoptosisEndogenous MetaboliteCytomegalovirusantiviralcytomegalovirusretinitisherpescancerInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Cidofovir dihydrate
    Cat. No.:
    HY-17438A
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.